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ABSTRACT 
 
 
The progression from compensated cardiac hypertrophy to decompensation and cardiac failure is 
accompanied by cardiac dilatation. As cardiac failure has a poor prognosis, it is imperative to 
prevent the progression to cardiac dilatation and heart failure. In this regard, an understanding of 
the mechanisms of cardiac dilatation is vital to guide optimal therapy to prevent heart failure. 
Although a number of factors have been shown to contribute to the development of cardiac 
dilatation, to date the role of alterations in cardiac myocyte dimensions remains unclear. Hence, 
the aim of the current study was to determine whether changes in cardiac myocyte dimensions 
contribute to the process of cardiac dilatation.  
Methods: Two models of cardiac dilatation in pressure-overload induced cardiac hypertrophy were 
assessed. One model was a natural progression model, in which 18 spontaneously hypertensive rats 
(SHR), were assessed at 23 months of age (an age when left ventricular hypertrophy is noted to 
have progressed to left ventricular decompensation, dilatation and heart failure in approximately 
50% of rats). The second model, a pharmacological model, was induced in 14 month old SHR 
(n=9) by chronic beta-adrenoreceptor activation [0.02mg/kg isoproterenol (ISO) twice daily for 4.5 
months]. Chronic beta-adrenoreceptor activation in SHR, enhances the progression from 
compensated left ventricular hypertrophy to left ventricular dilatation. Nine normotensive Wistar 
Kyoto (WKY) rats were the controls for both models. Left ventricular dilatation was defined as an 
increase in left ventricular radius determined at controlled filling pressures using piezo-electric 
transducers. The classification of rats as being in heart failure was based upon the presence of 
pleuropericardial effusions and / or atrial thrombi. Cardiac myocytes were isolated and dimensions 
determined using both light microscopy and flow cytometry. 
Results: Left ventricular radius was increased in SHR-Failure compared to SHR-Non-Failure 
(p<0.01), and in SHR-ISO compared to SHR-Control (saline administration) (p<0.01), hence 
confirming the presence of cardiac dilatation in both models. Although, cardiac myocyte length 
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was increased in all SHR groups compared to WKY (p<0.001), no differences were observed 
between SHR-Failure and SHR-Non-Failure, or between SHR-ISO and SHR-Control. No 
differences in cell length:width ratios or in cell widths were evident between the groups. The flow 
cytometry data confirmed the results obtained for cardiac myocyte lengths using microscopy. 
Moreover, a linear correlation (r=0.46, p=0.002) between flow cytometry and microscopy cardiac 
myocyte lengths was observed. Importantly, no relationships were evident between left ventricular 
radius and cardiac myocyte length (r=0.12, p=0.42 and r=0.14, p=0.35 for microscopic and flow 
cytometry lengths respectively). 
Conclusion: The results from the present study show that although pressure-overload hypertrophy 
is associated with lengthening of cardiac myocytes, no further changes occur with cardiac 
dilatation. Hence, alterations in cardiac myocyte dimensions do not contribute to the development 
of cardiac dilatation in pressure-overload models. 
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PREFACE 
Cardiovascular disease is one of the leading causes of morbidity and mortality in all parts of the 
world today. Almost all forms of cardiovascular disease progress to heart failure, which is the 
terminal endpoint of cardiovascular diseases. Hence, the progression to heart failure needs to be 
prevented. Chronic cardiovascular disease is initially accompanied by cardiac hypertrophy which 
is considered compensatory in that cardiac wall stress is maintained within normal levels; however 
compensatory cardiac hypertrophy progresses to cardiac decompensation and heart failure, a state 
in which cardiac wall stress is elevated. The increase in cardiac wall stress is primarily due to 
enlargement of the cardiac chamber volume and thinning of the cardiac chamber wall, a process 
termed detrimental cardiac remodelling or dilatation. As cardiac failure has a poor prognosis, it is 
imperative to prevent the progression to cardiac dilatation and heart failure. In this regard, an 
understanding of the mechanisms of cardiac dilatation is vital to guide optimal therapy to prevent 
heart failure.  
The mechanisms by which the cardiac tissue remodels to cause the dilatation are the topic of much 
debate. Both changes in the cardiac interstitium as well as changes in the cardiac myocytes are 
believed to play a role. In previous studies, adverse cardiac remodelling has been associated with 
increased cardiac interstitial fibrosis, but of the non-cross-linked form; cardiac myocyte apoptosis 
and necrosis; as well as cardiac myocyte hypertrophy due to changes in cell length. Although, 
some consensus has been reached regarding the role of the cardiac interstitium and cardiac 
myocyte death (apoptosis or necrosis); to date the role of alterations in the dimensions of cardiac 
myocytes remains unclear.  
Although, cardiac dilatation is thought to be mediated by increases in the length of cardiac 
myocytes, not all studies support this hypothesis. Indeed, although some studies show that 
increases in cardiac myocyte length are associated with increases in cardiac chamber dimensions 
or heart failure; a number of other studies show no relationship. Furthermore, data from 
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intervention studies failed to show changes in cardiac dimensions in parallel with changes in 
cardiac myocyte length. A number of reasons may explain the controversial results regarding the 
role of alterations in cardiac myocyte length in cardiac dilatation.  
Firstly, in some studies the increased cardiac myocyte length in patients with heart failure 
compared to healthy controls could be as a consequence of the differences in body weight and 
hence left ventricular (LV) weight between these two groups. The differences in body weight were 
due to a greater proportion of males in the heart failure group compared to the control group. 
Secondly, as the phase of the cardiac cycle determines cardiac chamber dimensions and cardiac 
myocyte length, possible differences between the heart failure and control groups in the phase of 
the cardiac cycle at the time of cardiac arrest may account for the differences in cardiac chamber 
diameter and cardiac myocyte length observed between these two groups in some human studies. 
Thirdly, in a number of studies in spontaneously hypertensive heart failure (SHHF) rats showing 
an association between cardiac myocyte length and cardiac chamber dimension, the animals in 
heart failure were significantly older than the control animals. As LV weight increases with age in 
hypertensive rats, and cardiac myocyte length is strongly associated with age and LV weight, the 
increases in cardiac myocyte length observed in the rats in heart failure may reflect age induced 
changes, rather than an association with adverse chamber remodelling (cardiac dilatation) and the 
development of heart failure. 
Fourthly, other than the studies in SHHF rats, no other studies have made direct comparisons of 
animals with cardiac pathology which have heart failure to animals with the same cardiac 
pathology but without heart failure. However, as discussed the increased cardiac myocyte length in 
SHHF rats may reflect increased age and hence increased LV weight compared to controls, rather 
than increased cardiac dimensions. Indeed, it has been shown that cardiac myocyte lengthening 
increased with age and occurred well before the development of heart failure in SHHF rats. 
Although the latter study suggests that changes in cardiac myocyte length are not responsible for 
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the development of heart failure, no measurements of cardiac dimensions were made in this study. 
To my knowledge no study to date has compared age-matched animals with the same cardiac 
pathology which have heart failure to those without heart failure. 
Lastly, the use of load dependent measures of cardiac chamber dimensions (echocardiography in 
vivo) in the presence of increased preloads may also contribute to the controversy. In this regard 
cardiac myocyte lengthening occurs as a consequence of the stretching of cardiac myocytes during 
increased preloads (filling volume or pressure). Moreover, when pulmonary capillary wedge 
pressure was normalised as a consequence of LV assist device support, a normalisation of both LV 
end diastolic diameter and cardiac myocyte length has been reported.  
Moreover, data from various intervention studies failed to show changes in cardiac dimensions in 
parallel with changes in cardiac myocyte length and hence the results of these studies do not 
support a role of changes in cardiac myocyte length in cardiac dilatation. Indeed, if increases in 
cardiac myocyte length were causally related to adverse cardiac remodelling, a reduction in cardiac 
myocyte length should be accompanied by a decrease in cardiac chamber dimensions. However, 
these intervention data need to be interpreted with caution in view of the use of load dependent 
measures of cardiac dimensions in these studies. 
The data to date provides no clear conclusion as to the possible role of cardiac myocyte length in 
adverse chamber remodelling. Hence, the aim of the current study was to determine whether 
changes in cardiac myocyte length contribute to the progression from compensatory cardiac 
hypertrophy to adverse chamber remodelling (cardiac dilatation) as measured using load 
independent methods in rats with heart failure compared to those not in heart failure.  
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1.0  INTRODUCTION 
 
One of the leading causes of morbidity and mortality in all parts of the world today is 
cardiovascular disease (American Heart Association, 2010). Over 80 million adults (more 
than one in three), in America alone have some form of cardiovascular disease (American 
Heart Association, 2010). Moreover, cardiovascular disease accounts for 16,7 million of 
deaths (29.2%) worldwide per annum (Frey et al., 2004). In South Africa, cardiovascular 
disease was reported to account for ~90 to 100 deaths per 100 000 population in 2006 
(Mayosi et al., 2009).  In addition, of the total cases reported on in a cardiology unit, at a 
hospital that services an urban developing community in South Africa, 43% were de novo 
presentations of heart failure (Stewart et al., 2008). Importantly, almost all forms of 
cardiovascular disease progress to heart failure, which is the terminal endpoint of 
cardiovascular diseases. Hence, the progression to heart failure needs to be prevented. 
 
In order to adequately prevent morbidity and mortality from heart failure, an understanding of 
the mechanisms underlying the progression to heart failure are paramount. In this regard a 
number of different models of heart failure have been investigated. A major predictor of 
progressive heart disease and an adverse prognosis is cardiac hypertrophy (Levy et al., 1990). 
Although, cardiac hypertrophy is initially a compensatory response to alterations in loading 
conditions (Grossman et al., 1975), prolonged hypertrophy ultimately leads to cardiac 
dilatation (increase in cardiac chamber dimensions), heart failure and subsequent death (Bing 
et al., 1995; Inoko et al., 1994; Lorell 1997; Spann et al., 1967). Factors which have been 
associated with the development of cardiac dilatation and heart failure (decompensation) in 
various models of cardiac hypertrophy, include unfavourable changes in the cardiac 
interstitium; enhanced cardiac myocyte apoptosis and necrosis; realignment of cardiac 
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myocytes within the ventricular walls (myocardial slippage) expression of foetal genes; and 
alterations in cardiac myocyte dimensions (Cohn et al., 2000; Ferrari et al., 2009; Frigerio & 
Roubina, 2005; Remme 2003). These changes occur in response to sustained pathological 
stress signals such as neurohumoral activation, the release of growth factors and 
inflammatory cytokines, and mechanical stretch (Cohn et al., 2000; Ferrari et al., 2009; 
Frigerio & Roubina, 2005; Remme 2003). These pathological signals are termed the 
mediators of adverse cardiac remodelling.   
 
Despite a plethora of studies investigating the various factors associated with the 
development of heart failure, the role of alterations in cardiac myocyte dimensions in the 
progression from compensatory cardiac hypertrophy to cardiac dilatation is unclear. In this 
regard, compensatory cardiac hypertrophy is generally associated with increases in cardiac 
myocyte width (Onodera et al., 1998; Zierhut et al., 1991); whereas alterations in cardiac 
myocyte length are thought to contribute to cardiac dilatation (Gerdes 2002). However, most 
studies showing increases in cardiac myocyte length in association with increases in left 
ventricular (LV) dimensions have used load dependent measures of cardiac chamber 
dimensions (Chen et al., 2010; Gerdes et al., 2010; Kajstura et al., 1995; Tamura et al., 1998; 
Wang et al., 1999; Yarbrough et al., 2010). Thus whether cardiac dilatation has indeed 
occurred in these studies is debatable. Moreover, although in some studies increases in load 
dependent measures of cardiac chamber diameter are associated with increases in cardiac 
myocyte dimensions (Gerdes et al., 2010; Janczewski et al., 2003; Kajstura et al., 1995; 
Schultz et al., 2007; Tamura et al., 1998; Toischer et al., 2010; Wang et al., 1999); other 
studies fail to show such relationships (Li et al., 2010; Schultz et al., 2007; Tamura et al., 
2000; Yarbrough et al., 2010). Nevertheless, an understanding of the role of cardiac myocyte 
hypertrophy in cardiac dilatation is essential to guide choices of optimal therapy to prevent 
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the progression from compensatory hypertrophy to decompensation.  
 
Hence, the aim of my studies was to determine the role of alterations in cardiac myocyte 
dimensions in the progression from concentric cardiac hypertrophy to cardiac dilatation. As 
the most prevalent form of heart failure is that associated with hypertensive heart disease 
(Remme et al., 2003), I chose to assess two models of cardiac dilatation in spontaneously 
hypertensive rats (SHR) with cardiac hypertrophy. Therefore, in the present chapter of my 
dissertation, I will discuss the role of cardiac dilatation in the development of heart failure 
and the importance of defining cardiac dilatation using load independent measurements. I 
will then review the literature on the factors (mediators and mechanisms) associated with the 
development of cardiac hypertrophy and the progression to decompensation and heart failure, 
with specific reference to the controversial role of alterations in cardiac myocyte dimensions.  
 
1.1 CARDIAC DILATATION AND HEART FAILURE 
 
In response to chronic elevations in cardiac wall stress (increases in loading conditions, such 
as chronic hypertension or post myocardial infarction), the heart undergoes hypertrophy 
(thickening of the ventricular wall) in an attempt to normalise wall stress. According to the 
law of La Place, wall tension or stress, is proportional to the product of pressure (P) and 
radius (r) and inversely proportional to wall thickness (h). Hence, an increased wall thickness 
in cardiac hypertrophy maintains a normal wall stress in the presence of increments in either 
pressure or volume (radius) within the cavity (Grossman et al., 1975). This process, termed 
compensatory cardiac hypertrophy, is generally associated with adequate cardiac systolic 
function, and a normal or increased ventricular wall thickness to radius ratio (Janicki et al., 
2004). However, diastolic function may be decreased due to the restriction of ventricular 
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filling by a thickened ventricular wall (Kai et al., 2005; Norton et al., 1993). The 
development of compensatory hypertrophy is due to the load-induced activation of various 
mediators which initiate cellular, molecular and genetic processes. 
 
As will be discussed in more detail later, persistent activation of these mediators over time, 
and consequently alterations in cellular, molecular and genetic processes eventually leads to 
cardiac decompensation (Remme, 2003). Cardiac decompensation is associated with a 
reduced ventricular wall thickness to radius ratio, ventricular enlargement and depressed 
cardiac systolic function (Janicki et al., 2004). This process of adverse cardiac remodelling 
(reduced ventricular wall thickness to radius ratio and ventricular enlargement), also termed 
cardiac dilatation, progresses with time to heart failure. Hence, cardiac dilatation is an 
important negative prognostic factor in patients with heart failure (Cohn et al., 2000; Udelson 
et al., 2002). Moreover, even in asymptomatic subjects without a prior history of heart 
failure, LV dilatation is associated with an increased risk of the development of heart failure 
(Vasan et al., 1997). It is therefore important to understand how cardiac remodelling 
contributes to the development of heart failure.  
 
One of the limitations of many studies assessing the role of cardiac remodelling in heart 
failure, and the mechanisms thereof, is the inability to define cardiac dimensions in a load-
independent model. In this regard, increases in cardiac filling volumes (increased preloads) 
would manifest as increased cardiac dimensions. Moreover, increases in cardiac afterload 
(increased cardiac wall stress as discussed above) would reduce stroke volume thereby 
increasing ventricular volumes at the end of systole, which would also manifest as increased 
cardiac dimensions. Hence, the correct definition of cardiac remodelling is an increase in 
cardiac diameter, or a decrease in the wall thickness to radius ratio, at a given filling volume. 
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Therefore, before discussing the impact of cardiac dilatation on cardiac function and the 
development of heart failure, I will first discuss in more detail the definition of cardiac 
dilatation and appropriate measurements thereof. 
 
1.1.1  Definition of Cardiac Dilatation 
Cardiac chamber dilatation is defined as an increase in chamber cavity volume or dimension 
as a consequence of a right shift in the diastolic pressure-volume relationship (Figure 1.1). 
Importantly, cardiac dilatation is not an increase in only the chamber cavity volume, as this 
may result from an enhanced blood volume or venous return (increased preload) without 
necessarily being accompanied by a right shift in the diastolic pressure-volume relationship. 
In addition, cardiac dilatation is not a right shift in the diastolic pressure-volume relationship 
produced by alterations in the slope of this relationship. Changes in the slope of the cardiac 
diastolic pressure-volume relationship occur as a consequence of alterations in chamber 
stiffness, which are usually mediated by modifications in the material properties of the 
myocardium (Gilbert and Glantz, 1989). However, cardiac chamber dilatation is the 
consequence of a right shift in the diastolic pressure-volume relationship due to an increase in 
the volume intercept of this relationship (Gibbs et al., 2004) (Figure 1.1). 
 
1.1.2  Appropriate Measurements of Cardiac Dilatation 
As increases in blood volume, venous return, and blood pressure (may decrease stroke 
volume); and decreases in cardiac contractility can result in increases in ventricular volumes, 
it is important that filling volumes are controlled when determining the relationship between 
diastolic pressure and volume. Hence, the in vivo assessment of the diastolic pressure-volume 
relationship using echocardiographic measures of cardiac dimensions is not appropriate. 
Indeed, blood volumes are related to body size, which may differ between for example  
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Figure 1.1 Example of a right-shift in the diastolic pressure-volume relationship 
 
The normal diastolic pressure-volume relationship is indicated by the solid line, and a right 
shift in the pressure-volume relationship, indicative of cardiac dilatation, is indicated by the 
dashed line. The volume intercept [volume at which left ventricular (LV) end diastolic 
pressure equals zero (V0)] is increased in the right shifted relationship. 
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normotensive and hypertensive rats (Badenhorst et al., 2003a; Tsotetsi et al., 2001; Veliotes 
et al., 2005). In addition, increases in cardiac afterload, such as increases in blood pressure or 
peripheral resistance in hypertension, would reduce stroke volume and hence increase filling 
volumes (more blood is left  behind  at  the  end  of  systole).  Moreover, the measurement of 
cardiac dimensions alone, without the measurement of the accompanying diastolic pressures 
is not appropriate. Indeed, as diastolic pressure increases, so does diastolic volume (Figure 
1.1). Hence, increases in chamber dimensions may be a manifestation of increases in filling 
pressures (increased preload) rather than measures of true cardiac dilatation.  
 
Nevertheless, many clinical and experimental studies have defined the presence of dilatation 
using non-invasive measurements such as echocardiography and ventriculography. Hence, 
whether cardiac dilatation was indeed present is questionable. Indeed increases in filling 
pressures were noted in many of these studies (Chen et al., 2010; Gerdes et al., 2010; 
Kajstura et al., 1995; Tamura et al., 1998; Wang et al., 1999; Yarbrough et al., 2010; 
Zefeiridis et al. 1998). Although in clinical studies there is no alternative to non-invasive 
measurements; of greater concern is the use of such measurements in terminal experimental 
studies. In this regard, in many animal based studies, the groups differ in age (Gerdes et al., 
1996; Tamura et al., 1998). As age is associated with increased LV weight (Gerdes et al. 
1996), and increased left ventricular weight is correlated with cardiac myocyte length 
(Campbell et al. 1991; Capasso et al. 1992), and age (Tamura et al., 1998), any differences in 
cardiac dimensions could be attributed to differences in age and hence heart weight rather 
than true differences in the dimensions of the heart. In other words the increased left 
ventricular weight and hence cardiac myocyte length is likely to reflect growth effects during 
aging. 
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Therefore, in order to appropriately define the presence of cardiac dilatation, ventricular 
pressures need to be determined and ventricular filling volumes need to be controlled. In this 
manner the diastolic pressure-volume relationship can be constructed and hence the volume 
at which pressure is 0 mm Hg (ie. the volume intercept) can be determined. Importantly, very 
few studies have accurately defined dilatation using pressure-volume relationships. In this 
regard, no study assessing the role of cardiac myocyte dimensions in heart failure, has 
accurately defined the presence of dilatation.  
 
1.1.3  Role of Cardiac Dilatation in the Development of Heart Failure 
Initially it was thought that cardiac dilatation was a remodeling process that began in order to 
prevent the progressive increases in filling pressures associated with heart failure (Ertl et al., 
1991). In essence, it was believed that the decreased contractility in heart failure and hence 
increased filling volumes (Patterson and Adams, 1996), were necessary in order to maintain 
stroke volume via the Frank-Starling effect (Grossman et al., 1975). However, the increased 
filling volumes would be accompanied by increases in filling pressures and hence pulmonary 
capillary hydrostatic pressures may be elevated resulting in pulmonary congestion. It was 
therefore believed that in order to accommodate enhanced filling volumes at normal filling 
pressures a right shift in the diastolic pressure-volume occurred.   
 
However, more recently, cardiac dilatation has been shown to be a precursor of pump 
dysfunction and clinical heart failure (Gaudron et al., 1993; Pfeffer et al., 1992; Vasan et al., 
1997). In a 3 year prospective study in patients post myocardial infarction, those patients who 
had progressive dilatation also had a progressive decline in ejection fraction and an increase 
in pulmonary capillary wedge pressure (Gaudron et al., 1993); whereas in those patients with 
no dilatation, LV ejection fraction did not decline and pulmonary wedge pressure remained 
10 
 
within normal values. Hence cardiac dilatation post myocardial infarction results in the 
development of heart failure. In addition, in an 11-year follow-up study of people who had 
not sustained a myocardial infarction and who did not have congestive heart failure at 
enrolment, increments in LV internal dimension increased the risk of development of 
congestive heart failure (adjusted hazard ratio of 1.47 for a one standard deviation increase in 
LV end diastolic diameter indexed for height) (Vasan et al., 1997). Moreover, intervention 
studies have shown that the alleviation of LV enlargement post myocardial infarction 
prolongs survival and reduces mortality and morbidity due to major cardiovascular events 
(Pfeffer et al., 1992; St John Sutton et al., 1997). Hence, the process of cardiac dilatation has 
to be seen as a cause of heart failure as opposed to its consequence. 
 
There are a number of additional observations which support the role of cardiac dilatation in 
the development of heart failure. Firstly, in the presence of compensatory cardiac 
hypertrophy (increases in wall thickness) in response to pressure overload, there is no 
evidence of systolic heart failure (Wang et al., 1999; Onodera et al., 1998; Woodiwiss et al., 
1995; Yousef et al., 2000). Secondly, the neurohumoral factors that maintain systolic 
function in the hypertrophied heart, in the long-term are detrimental to the myocardium. 
Indeed, these neurohumoral factors promote cardiac dilatation and ultimately lead to systolic 
dysfunction (Woodiwiss et al., 1995; Yousef et al., 2000). Lastly, there is evidence to show 
that maladaptive changes in myocardial tissue occur long before symptoms of heart failure 
(Onodera et al., 1998). Hence adverse cardiac remodelling, which consists of both 
macroscopic and microscopic changes in the myocardium, precedes heart failure and 
therefore contributes to, instead of results from, heart failure (Onodera et al., 1998). The 
question of how cardiac dilatation produces pump dysfunction and heart failure therefore 
arises.  
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1.1.4  How Does Cardiac Dilatation Produce Pump Dysfunction? 
Changes in pump function are best explained by the Frank-Starling relationship. Figure 1.2 
illustrates the normal Frank-Starling relationship and the changes that occur in association 
with either an enhanced pump function or a decreased pump function. A left and upward shift 
of  the  curve  compared  to  normal  (an  enhanced  pump  function)   occurs   when  intrinsic 
myocardial contractility increases (such as in the presence of increased circulating 
catecholamines   as   may   occur  with  exercise); or  afterload  decreases (such  as  following 
vasodilatation); or the relationship between wall thickness and internal radius increases (such 
as with compensatory cardiac hypertrophy). In contrast, displacement to the right and 
downward from the normal occurs when ventricular contractility is depressed; or afterload is 
increased; or the heart dilates as is the case in most forms of heart failure due to systolic 
functional abnormalities. Although the impact of changes in intrinsic myocardial contractility 
and the resistance to blood flow on systolic function, are relatively easy concepts to grasp, 
cardiac dilatation is sometimes a conceptually difficult issue. Hence, how does cardiac 
dilatation produce deleterious effects on pump function? 
 
As chamber dilatation is associated with an increased cavity volume (and hence radius), and a 
reduced wall thickness, according to La Place’s law, wall tension or stress (afterload) will be 
increased. As wall stress determines myocardial oxygen consumption, the myocardial oxygen 
demand-to-supply ratio may be increased in a dilated ventricle, and a demand-to-supply 
mismatch may subsequently decrease cardiac contraction. However, when systolic function 
was measured using a stress (or load)-independent measure of pump function (end systolic 
elastance) in an animal model of congestive cardiac failure and pump dysfunction associated 
with massive cardiac dilatation (Norton et al., 2002), pump function was reduced without 
parallel changes in myocardial contractility. These data would suggest that a mechanism 
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Figure 1.2 Example of changes in the Frank-Starling relationship 
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unrelated to stress or load-induced effects contributes to pump dysfunction in cardiac 
dilatation. It is possible that inappropriate force transduction occurs in dilated ventricles 
during myocyte contraction, which in-turn leads to pump dysfunction (Sallin 1969). 
Alternatively, in a dilated ventricle, larger chamber volumes may be required to produce 
cardiomyocyte stretch and hence to recruit the Frank-Starling effect. Indeed, when the 
structure of the ventricle changes, the mechanics of systolic output are affected, thus resulting 
in a low-output state (Laskey et al., 1984; Cohn et al., 2000). 
 
Having established that cardiac dilatation is a cause rather than a consequence of pump 
dysfunction and heart failure; in order to reduce morbidity or mortality from progressive 
heart failure treatments which prevent or reverse adverse cardiac remodelling are required. 
The choice of effective therapy is based on the knowledge of the mediators and the 
mechanisms responsible for cardiac remodelling. I will therefore discuss what is known to 
date regarding the mediators of cardiac dilatation and the role of various potential 
mechanisms. 
 
1.2 MEDIATORS OF CARDIAC HYPERTROPHY AND ADVERSE 
CARDIAC REMODELLING 
 
The generally accepted theory is that the mediators responsible for compensatory cardiac 
hypertrophy, when sustained are ultimately responsible for the progression to adverse cardiac 
remodelling and heart failure. I will therefore discuss what is known regarding the mediators 
of compensatory hypertrophy as well as the how these factors are thought to mediate cardiac 
dilatation and the development of heart failure.  
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Compensatory cardiac hypertrophy and cardiac dilatation occur due to the independent and 
interactive effects of three extrinsic mediators on the heart, namely: (1) neurohormones; (2) 
growth factors and inflammatory cytokines; and (3) mechanical stretch receptors in the cell 
membranes, which activate signalling pathways intracellularly (Cohn et al., 2000; Ferrari et 
al., 2009; Frigerio & Roubina, 2005; Remme 2003).   
 
These extrinsic mediators act via various intracellular pathways [mitogen activated protein 
(MAP) kinase; nuclear factor ĸB; protein kinase B] to activate nuclear transcription, which 
leads to cellular hypertrophy, necrosis, apoptosis and fibrosis (Katz 2002; Opie et al., 2006; 
Yousef et al., 2000). The nature of the signalling stimulus is believed to determine which 
intracellular  pathways  are  activated  and  hence  whether  compensatory cardiac 
hypertrophy or  cardiac  dilatation  occurs (Ferrari et al., 2009; Hill & Olson 2008; Opie et 
al., 2006). 
   
1.2.1 Role of Neurohormones in Compensatory Cardiac 
Hypertrophy and the Progression to Cardiac Decompensation 
and Heart Failure 
Neurohormonal activation [activation of the sympathetic nervous system (SNS) and the 
renin-angiotensin-aldosterone system (RAAS)] is known to occur in response to increases in 
cardiac wall stress. Indeed, circulating concentrations of noradrenaline are increased in 
persons with hypertension and LV hypertrophy (Agabiti-Rosei et al., 1987; Kelm et al., 
1996). In addition, the RAAS is activated in the hypertrophied and failing heart (Danser et 
al., 1997; Iwai et al., 1995). Initially, the increased activity of the SNS and RAAS occur in 
order to normalise wall stress and to preserve contractile performance; however continual 
activation of the SNS (Badenhorst et al., 2003b; Gibbs et al., 2004; Veliotes et al., 2005) and 
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the RAAS (Mizuno et al., 2001; Schunkert et al., 1993) have been shown to induce cardiac 
dilatation and heart failure. Indeed, neurohumoral activation in heart failure (Hasking et al., 
1986), is a major factor responsible for the progression of heart failure (Bristow 1997; Cohn 
et al., 1984). 
 
1.2.1.1 Role of the Sympathetic Nervous System 
Initially in compensatory hypertrophy, in response to increased catecholamines, the inotropy 
of the cardiac myocytes is increased through post receptor activation of adenylate cyclase and 
consequent increases in the intracellular concentration of the second messenger cyclic 
adenosine monophosphate (cAMP). This response will improve the cardiac output through an 
increased myocardial contraction. However, sustained elevations in catechoamines in the 
presence of increased pressure loads will increase myocardial oxygen demand (a 
consequence of increased inotrope as well as increased afterload, due to alpha adrenergic 
mediated vasoconstriction), which may outstrip myocardial oxygen supply, as increased 
vascularisation does not occur in parallel with myocardial hypertrophy (Weisman et al., 
1988). One of the consequences of oxygen demand-to-supply imbalance is tissue necrosis. As 
cardiac myocytes within the syncitium die, the viable cardiac myocytes within the syncitium 
are stretched hence possibly resulting in side-to-side slippage and ultimately cardiac 
dilatation (Figure 1.3). Indeed, myocyte slippage in end stage dilated cardiomyopathy has 
been well documented (Beltrami et al., 1995; Linzbach 1960). 
 
Sustained (or chronic) activation of the SNS not only induces cardiac myocyte death through 
hemodynamic mechanisms as described above, but also via direct mechanisms. Indeed, 
excessive concentrations of adrenergic agonists promote necrosis (Esler et al., 1997) and 
apoptosis (Communal et al., 1998; Singh et al., 2001).  Adrenergic-induced cardiac myocyte 
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Figure 1.3 Schematic representation showing possible mechanisms of cardiac 
dilatation.  
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apoptosis is mediated via activation of β1-adrenergic receptor cAMP-dependent protein 
kinase A and mitogen-activated protein kinase (MAPK) pathways. Adrenergic activation may 
also promote cardiomyocyte apoptosis indirectly via stimulation of the RAAS (see 1.2.1.2 
below) or through increases in myocardial expression of inflammatory cytokines (see 1.2.2 
below). Similar  to  necrosis  the  consequences  of  apoptosis  are  stretching  of  the  viable  
cardiac myocytes within the syncitium are stretched hence possibly resulting in side-to-side 
slippage and ultimately cardiac dilatation (Figure 1.3). In addition to cardiac myocyte death, 
chronic β-adrenergic activation results in unfavourable alterations in the cardiac interstitium, 
which result in decreased tethering of the cardiac myocytes (Figure 1.3). Indeed, as will be 
discussed below (see 1.4.1) increases in the non-cross-linked collagen content of the 
myocardium have been demonstrated in association with cardiac dilatation after chronic 
administration of the β-adrenergic agonist isoproterenol (Woodiwiss et al., 2001). Although, 
isoproterenol, has been shown to stimulate the activity of matrix metalloproteinases (MMPs) 
in isolated cardiac myocytes (Coker et al., 2001), which would increase collagen turnover 
thereby reducing time available for cross-linking to occur (Woodiwiss et al., 2001); it is more 
likely that the changes in the characteristics of myocardial collagen are mediated  by 
activation of the RAAS, as the decreased collagen cross-linking could be prevented by both 
angiotensin-converting enzyme inhibitor administration (Woodiwiss et al., 2001) as well as 
aldosterone receptor blockade (Veliotes et al., 2005). 
 
Although, adrenergic activation, together with activation of inflammatory cytokines, has been 
associated with cardiac myocyte hypertrophy (increased cell width) (Tarone & Lembo, 
2003); to date there is no evidence to implicate adrenergic activation in promoting 
lengthening of cardiac myocytes.  
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Evidence of the potential role of activation of the SNS in mediating adverse cardiac 
remodelling is provided by the detection of substantially increased plasma concentrations of 
noradrenaline and adrenaline in patients with heart failure (Anand et al., 2003; Cohn et al., 
1984; Francis et al., 1993; Swedberg et al., 1990), and the relationship of these 
concentrations to the severity of pump dysfunction (Kluger et al., 1982) and heart failure 
(Sigurdsson et al., 1994). Furthermore, a number of studies have demonstrated that β-
adrenergic receptor blocking agents reduce cardiac cavity dimensions (Gerson et al., 2002; 
Metra et al., 2003; Packer et al., 1996; Toyama et al., 2003; Waagstein et al., 1993a; 
Waagstein et al., 1993b).   
 
1.2.1.2 Role of the Renin-Angiotensin-Aldosterone System 
Initially activation of the RAAS is compensatory in nature in that RAAS mediated fluid 
retention improves venous return and thus cardiac output (via the Frank-Starling effect). 
However sustained elevations in the RAAS are detrimental. Indeed, both angiotensin II and 
aldosterone have been shown to promote cardiac myocyte apoptosis (De Angelis et al., 
2002), and hence the potential for side-to-side slippage of cardiac myocytes (Figure 1.3).  
 
Activation of the RAAS is also likely to play a role in the unfavourable changes in the 
characteristics of myocardial collagen, as decreased collagen cross-linking associated with 
cardiac dilatation could be prevented by both angiotensin-converting enzyme inhibitor 
administration (Woodiwiss et al., 2001) as well as aldosterone receptor blockade (Veliotes et 
al., 2005). In addition, angiotensin II and aldosterone have been shown to stimulate collagen 
synthesis (Brilla et al., 1994). 
  
Although, angiotensin II acting as a growth factor has been shown to mediate cardiac 
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myocyte hypertrophy by increasing cell width (Sadoshima et al., 1997; Serneri et al., 1999), 
the role of the RAAS in cardiac myocyte lengthening is as yet unclear.  
 
Nevertheless, the role of the RAAS in adverse cardiac remodelling is substantiated by 
intervention data showing reductions in cardiac dimensions following the administration of 
ACEI to patients in heart failure (Greenberg et al., 1995; Konstam et al., 1992). 
 
1.2.2  Role of Growth Factors and Inflammatory Cytokines 
Growth factors such as insulin-like growth factor are thought to mediate cellular hypertrophy 
via the protein kinase B pathway (Opie et al., 2006). Activation of this pathway promotes 
cardiac myocyte growth (increased cell width) and inhibits apoptosis (Matsui & Rosenzweig, 
2005). Hence, activation of insulin-like growth factor is important in mediating compensatory 
hypertrophy, but possibly plays no role in the transition to cardiac decompensation. In 
comparison transforming growth factor β, similar to angiotensin II, activates fibroblasts 
hence promoting collagen formation and fibrosis (Hein et al., 2003; Kuwahara et al., 2004). 
Increased fibrosis (as discussed below) is important in both compensatory hypertrophy and 
dilatation. Inflammatory cytokines, such as tumour necrosis factor α, seem to have a dual 
role. At low concentrations these cytokines mediate compensatory hypertrophy; whereas at 
high concentrations they may play a role in mediating cardiac dilatation and heart failure 
(Tarone & Lembo, 2003). Lastly, cardiac myocyte apoptosis may be promoted by increased 
myocardial expression of inflammatory cytokines as a consequence of adrenergic activation 
(Baumgarten et al., 2000). However, intervention studies targeting inflammatory cytokines 
proved disappointing in patients with heart failure, in that no differences were observed in 
rates of death or hospitalisation due to chronic heart failure compared to placebo (Anker & 
Coats 2002).   
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1.2.3  Role of Stretch Receptors (Cardiac Myocyte Stretch) 
The hypertrophy of cardiac myocytes is also regulated by stretch mediated by hemodynamic 
loading conditions (Russell et al., 2010); in association with increased activation of the 
RAAS (Kudoh et al., 1997; Sadoshima et al, 1993. In this regard increases in ventricular 
volume (increased diastolic strain) are thought to be responsible for increases in cardiac 
myocyte length (Russell et al., 2010); whereas increases in pressure (increased systolic stress) 
produce increases in cardiac myocyte width (Russell et al., 2010). Consequently, 
compensated cardiac hypertrophy is associated with increases in cardiac myocyte width and 
cross-sectional area in proportion to increases in length (Onodera et al., 1998; Zierhut et al., 
1991). In comparison, in the decompensated state, changes in cardiac myocyte length may 
exceed increments in cardiac myocyte width (Fedak et al., 2005; Gerdes & Capasso 1995).  
 
1.3 PROPOSED MECHANISMS OF COMPENSATORY 
CARDIAC HYPERTROPHY 
 
Mechanisms of compensatory cardiac hypertrophy include changes in the cardiac interstitium 
as well as changes in the cardiac myocytes. In essence compensatory cardiac hypertrophy is 
associated with increased cardiac interstitial fibrosis, increased collagen cross-linking, as well 
as cardiac myocyte hypertrophy (increased cell width). These mechanisms will be discussed 
separately below.  
 
1.3.1  Role of Collagen and Interstitial Changes 
In compensatory cardiac hypertrophy, in response to increased angiotensin II, aldosterone, 
transforming growth factor β and noradrenaline, cardiac fibroblasts are activated (Hein et al., 
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2003; Kuwahara et al., 2004; Weber et al., 1990; Weber et al., 1993). Consequently, collagen 
synthesis is enhanced. In addition, matrix metalloproteinases (MMPs), which are responsible 
for collagen degradation (Gunasinghe et al., 2001) are inhibited (Janicki et al., 2004), hence 
collagen deposition exceeds collagen degradation. In addition, compensatory hypertrophy is 
associated with increased collagen cross-linking, mediated by increased activity of the cross-
linking enzyme lysyl oxidase (Hermida et al., 2009). As a consequence of increased fibrosis 
and collagen cross-linking, there is adequate tethering of cardiac myocytes to the interstitial 
matrix. Hence in the presence of increased loading conditions the structural morphology of 
the cardiac chamber in maintained.  
 
1.3.2 Role of Cardiac Myocyte Hypertrophy Due to Increases in Cell 
Width 
The initial response to high pressures in the cardiovascular system is cellular hypertrophy by 
means of increases in cardiac myocyte width, which result in increases in chamber wall 
thickness (Grossman et al., 1975). In response to increased afterload (increased cardiac wall 
stress due to high pressures in the cardiovascular system), cardiac hypertrophy occurs in 
order to increase cardiac wall thickness and hence to decrease cardiac wall stress (via La 
Place’s law) (Grossman et al., 1975). In addition, cellular hypertrophy occurs in an attempt to 
relieve the heart of the raised filling pressures (increased preload) by increasing the output of 
the heart through an increased stroke volume or systolic function. The greater stroke volume 
is achieved by the increased muscle mass which generates a stronger muscle force. Katz et al. 
(2002), in a review article, refer to this process of hypertrophy by the heart and its myocytes 
as an attempt to ‘grow their way out of trouble’. In other words, in the presence of increased 
loading conditions, the ventricles need to grow (through hypertrophy) in order to reduce the 
loading conditions.  
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The initial response of cardiac muscle tissue to increased pressure load conditions is to 
increase cardiac myocyte width through parallel additions of cardiac myofilaments (Onodera 
et al., 1998; Zierhut et al., 1991), thus resulting in thickening of the myocardial wall. In 
models of pressure overload (hypertension), both Onodera et al. 1998 and Zierhut et al. 1991, 
showed that initially cardiac hypertrophy was accompanied by increases in cardiac myocyte 
width but not by changes in cardiac myocyte length. Hence, the initial response of the cardiac 
myocyte to augmented afterload is to increase in width but not in length (Onodera et al., 
1998; Zierhut et al., 1991). As a consequence of increases in cardiac wall thickness 
subsequent to cellular hypertrophy, the luminal radius is reduced (Janicki et al., 2004). An 
increase in the width of the ventricular wall with a concomitant reduction in the luminal 
radius is commonly referred to as concentric or compensatory hypertrophy (Janicki et al., 
2004). This initial form of hypertrophy in response to increased cardiovascular loading 
conditions is considered compensatory in nature (Janicki et al., 2004). 
 
1.4 PROPOSED MECHANISMS OF ADVERSE CARDIAC 
REMODELING 
 
The mechanisms by which the cardiac tissue remodels to cause the dilatation are the topic of 
much debate. However, as with compensatory cardiac hypertrophy both changes in the 
cardiac interstitium as well as changes in the cardiac myocytes are believed to play a role. In 
essence adverse cardiac remodelling is associated with increased cardiac interstitial fibrosis, 
but of the non-cross-linked form; cardiac myocyte apoptosis and necrosis; as well as cardiac 
myocyte hypertrophy due to changes in cell length. These mechanisms will be discussed 
separately below. 
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1.4.1  Role of Collagen and Interstitial Changes 
Sustained elevations in noradrenaline, angiotensin II, aldosterone and transforming growth 
factor β increase collagen synthesis (Boluyt et al., 1995; Hein et al., 2003; Weber & Brilla 
1991; Weber et al., 1993). However, sustained elevations in these neurohormones are also 
accompanied by increases in MMP activity (Banfi et al., 2005; Mujundar & Tyagi, 1999; 
Spinale et al., 1998). Therefore, both collagen synthesis and degradation are enhanced. 
Indeed, reductions in cardiac chamber dimensions following the use of LV assist devices are 
generally accompanied by increases rather than decreases in myocardial collagen 
concentrations (Li et al., 2001; Scheinin et al., 1992); whereas pacing-induced cardiac 
dilatation (Spinale et al., 1991) and adrenergic-induced cardiac dilatation (Woodiwiss et al., 
2001) are accompanied by decreases in myocardial collagen concentrations. Hence, 
alterations in the characteristics of myocardial collagen, rather than in myocardial collagen 
concentrations, are more likely to contribute toward chamber dilatation. 
 
As a consequence of enhanced collagen turnover (increased synthesis and degradation), the 
time available for collagen cross-linking to occur is decreased (Woodiwiss et al., 2001). A 
reduction in collagen cross-linking reduces the capacity to tether cardiac myocytes (Li et al., 
2001; Mann & Spinale 1998), resulting in side-to-side slippage of cardiac myocytes and 
hence the development of cardiac dilatation (Olivetti et al., 1990; Woodiwiss et al., 2001) 
(Figure 1.3).  Indeed, non cross-linked collagen is associated with cardiac dilatation and 
systolic dysfunction (Capasso et al., 1989; Gunja-Smith et al., 1996; Spinale et al., 1996; 
Woodiwiss et al., 2001).  
 
In addition, non cross-linked collagen may be more susceptible to degradation by MMPs thus 
resulting in decreased tethering of cardiac myocytes and cardiac dilatation (Badenhorst et al., 
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2003b; Woodiwiss et al., 2001). Indeed, genetic decreases in the susceptibility of collagen to 
degradation, reduce the degree of dilatation which accompanies pressure-overload states 
(Papadimitriou et al., 1974). In addition, increased myocardial expression and activation of 
MMPs has been demonstrated in patients with heart failure or in patients with a reduced 
systolic function and cardiac dilatation (Li et al., 2001; Polyakova et al., 2004; Reddy et al., 
2004; Spinale et al., 2000; Spinale, 2002), and in animal models of pump dysfunction and 
cardiac dilatation (King et al., 2003; Mukherjee et al., 2003; Peterson et al., 2001; Rohde et 
al., 1999; Sakata et al., 2004; Spinale et al., 1998). Moreover, MMP inhibition attenuates left 
ventricular dilatation in animal models of pacing-induced heart failure (Spinale et al., 1999), 
myocardial infarction (Mukherjee et al., 2003; Rohde et al., 1999) and heart failure in the 
spontaneously hypertensive rat (Peterson et al., 2001); and a loss of MMP inhibitory control 
of MMPs, through a gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 
1 (TIMP-1), has been demonstrated to lead to ventricular dilatation in mice (Roten et al., 
2000). 
 
1.4.2   Role of Cardiac Myocyte Apoptosis and Necrosis 
Cardiac myocyte cell death may occur via an active, regulated, energy demanding process 
controlled by an inherited genetic program (Sabbah & Sharov, 1998) resulting in apoptosis. 
Alternatively cardiac myocyte death may occur via the unregulated process of necrosis (Kang 
& Izumo, 2000). Due to sustained increases in noradrenaline and angiotensin II, and the 
consequence of myocardial oxygen demand exceeding supply, necrosis and apoptosis of 
cardiac myocytes occurs.  Cardiac myocyte death could reduce the capacity to tether cardiac 
myocytes hence promoting side-to-side slippage of cardiac myocytes (Figure 1.3). Hence, 
cardiac myocyte death mediated either by tissue apoptosis or necrosis may promote the 
development of cardiac dilatation (Yussman et al., 2002).  Indeed, cardiac dilatation occurs 
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following myocardial infarction and cellular necrosis (Anversa et al., 1985; Zimmer et al., 
1990; Olivetti et al., 1990). 
 
1.4.3 Role of Cardiac Myocyte Hypertrophy Due to Increases in Cell 
Length 
Although, cardiac dilatation is thought to be mediated by increases in the length of cardiac 
myocytes, not all studies support this hypothesis. Indeed, although some studies show that 
increases in cardiac myocyte length are associated with increases in cardiac chamber 
dimensions or heart failure (Beltrami et al., 1994; Gerdes et al., 1996; Gerdes et al., 2010; 
Janczewski et al., 2003; Kajstura et al., 1995; Pangonyte et al., 2008; Schultz et al., 2007; 
Tamura et al., 1998; Toischer et al., 2010; Wang et al., 1999; Zefeiridis et al., 1998); a 
number of other studies show no relationship (Li et al., 2010; Schultz et al., 2007; Tamura et 
al., 2000; Yarbrough et al., 2010). Furthermore, data from intervention studies failed to show 
changes in cardiac dimensions in parallel with changes in cardiac myocyte length (Kuzman et 
al., 2007; Li et al., 2010; Schultz et al., 2007; Tamura et al., 2000). Therefore, it is important 
to discuss possible reasons for the controversial results regarding the possible role of 
alterations in cardiac myocyte length in cardiac dilatation. 
 
1.4.3.1 Are Changes in Cardiac Dimensions Associated with Changes 
in Cardiac Myocyte Length?  
1.4.3.1.1 Data From Human Studies: 
Previous data obtained in human studies on the possible association between cardiac myocyte 
length and cardiac dimensions are summarised in Table 1. The data from human studies 
indicate that increases in cardiac myocyte length accompany increases in cardiac chamber 
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Table 1.1: Summary of human data addressing possible association of cardiac remodelling with alterations in myocyte morphology 
Pathology/Model/Intervention Measure of 
Cardiac 
Remodeling 
Function / 
Presence of 
Heart 
Failure 
Method of 
Cardiac 
Assessment  
Myocyte 
Morphology 
Method of 
Cell 
Measurement 
Reference My Interpretation 
Cardiac transplantation in patients 
with congestive heart failure due to 
ischemic cardiomyopathy (males) 
 transverse 
chamber 
diameter 
Patients with 
congestive 
HF 
Anatomical 
measurement 
 length 
 
Measurement 
of cells in 
histological 
sections 
Beltrami et 
al 1994 
 LVEDD associated with 
 cell length in patients in 
HF, but assessments all 
anatomical 
Cardiac transplantation in patients 
with congestive heart failure due to 
ischemic cardiomyopathy (males) 
Not done  EF Echo (in 
vivo) 
 length 
 
Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes 
Gerdes et 
al 1992 
 EF associated with  
cell length, but no LV 
dimension data. All 
patients were male & had 
higher body weight than 
controls (all females), 
hence  cell length may 
be due to  body weight 
and therefore  heart 
weight in patients  
Cardiac transplantation in patients 
with heart failure (12 ischemic & 
18 nonischemic) (80% males 
versus 50% males in control 
group) 
 
LV assist device support in 10 
patients with heart failure (80% 
males) 
 LVEDD 
 
 
 
 
Normalisation 
of  LVEDD 
 PCWP 
 
 
 
 
Normalisatio
n of PCWP 
Echo (in 
vivo) 
 length 
 
 
 
 
Normalisation 
of length 
Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes 
Zafeiridis 
et al 1998 
 LVEDD associated with 
 cell length, but  
LVEDD is a preload 
induced effect ( PCWP). 
More patients were male & 
hence had higher body 
weight than controls, 
therefore  cell length 
may be due to  body 
weight and therefore  
heart weight in patients 
Within 12 hours of MI in patients 
who died from first MI compared 
with patients who died after second 
or subsequent MI (males)  
 endocardial 
surface area 
No clinical 
symptoms of 
HF 
Anatomical 
measurement 
 length in 
both MI groups 
 
 
Measurement 
of cells in 
histological 
sections 
Pangonyte 
et al 2008 
 cell length occurs 
during ischaemia and prior 
to MI and development of 
HF 
, increase;  decrease; echo, echocardiography; EF, ejection fraction; HF, heart failure; LV, left ventricle; LVEDD, left ventricular end diastolic 
diameter; PCWP, pulmonary capillary wedge pressure; ,  and no change are in comparison to control group unless otherwise stated  
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diameter (Beltrami et al., 1994; Pangonyte et al., 2008; Zefeiridis et al., 1998). However, it 
would be incorrect to draw a conclusion that adverse chamber remodelling (cardiac 
dilatation) is associated with increases in cardiac myocyte length, from this data for a number 
of reasons.  
 
Firstly, in one these studies (Zefeiridis et al., 1998), echocardiography in vivo was used to 
determine left ventricular end diastolic diameters and hence the cardiac chamber dimension 
measurements  were  load  dependent.  As  increases  in pulmonary capillary  wedge  pressure 
were noted in the patients in this study (Zefeiridis et al., 1998), the increased chamber 
dimensions are likely to be due to increases in LV preload. In this regard, as discussed 
previously, cardiac myocyte lengthening occurs as a consequence of the stretching of cardiac 
myocytes during increased preloads (Ferrari et al., 2009). Indeed, Zefeiridis et al. (1998) 
showed a normalisation of both LV end diastolic diameter and cardiac myocyte length, when 
pulmonary capillary wedge pressure was normalised as a consequence of LV assist device 
support. Left ventricular assist devices divert blood from the left atrium to the aorta, thereby 
removing the preload and afterload to the left ventricle. Hence these devices are used to 
provide haemodynamic support for patients with end-stage heart failure awaiting 
transplantation.  
  
Secondly, in the study of Beltrami et al. (1994), the hearts were collected at autopsy for the 
control group and during cardiac transplantation for the heart failure group. Measurements of 
cardiac chamber dimensions and cardiac myocyte length were made anatomically; however 
no mention was made as to whether the hearts were arrested in diastole or systole. It is 
possible that during transplantation the hearts were arrested in diastole, as this was part of the 
surgical procedure at the time; whereas in the control group the phase of the cardiac cycle at 
the time of arrest was unknown as 70% of the control hearts were obtained from individuals 
in whom death was sudden due to traumatic injury. As the phase of the cardiac cycle 
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determines cardiac chamber dimensions and cardiac myocyte length, possible differences 
between the heart failure and control groups in the phase of the cardiac cycle at the time of 
cardiac arrest may have accounted for the differences in cardiac chamber diameter and 
cardiac myocyte length between these two groups.      
 
Thirdly, in some studies the increased cardiac myocyte length in patients compared to 
controls could be as a consequence of the differences in body weight and hence LV weight 
between these two groups (Gerdes et al., 1992; Zafeiridis et al., 1998). Indeed, in one study 
all patients in heart failure were males; whereas all healthy controls were females (Gerdes et 
al., 1992). As the males had greater body weights than the controls (Gerdes et al., 1992), the 
increased cardiac myocyte length may be attributed to the greater body size in the males 
rather than to the presence of heart failure. Similarly, in another study the increased cardiac 
myocyte length in the patients compared to the controls may in part be attributed to the 
greater proportion of males in the heart failure group compared to the control group 
(Zafeiridis et al., 1998).  
 
Lastly, in a study assessing cardiac myocyte length and cardiac dimensions within 12 hours 
of death due to a first myocardial infarction compared to within 12 hours of death from a 
second or subsequent myocardial infarction, increases in cardiac myocyte length were noted 
in both groups with myocardial infarction compared to a control group who died from non-
cardiovascular causes (Pangonyte et al., 2008). Importantly neither of the myocardial 
infarction groups had clinical symptoms of heart failure.  Therefore, from this study it can be 
concluded that increases in cardiac myocyte length occur during ischaemia before myocardial 
infarction and the development of heart failure.  
 
Hence, from human studies published to date, the potential relationship between adverse 
chamber remodelling (cardiac dilatation) and cardiac myocyte length is unclear. 
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1.4.3.1.2  Data from Animal Experimental Models: 
Previous data on the possible association between cardiac myocyte length and cardiac 
dimensions obtained from animal experimental models are summarised in Table 2. Although 
a number of studies have attempted to address the question of the relationship between 
cardiac myocyte length and cardiac dimensions in various animal experimental models; the 
data is controversial. Some studies show that increases in cardiac myocyte length are 
associated with increases in cardiac chamber dimensions or heart failure (Gerdes et al., 1996; 
Gerdes et al., 2010; Janczewski et al., 2003; Kajstura et al., 1995; Schultz et al., 2007; 
Tamura et al., 1998; Toischer et al., 2010; Wang et al., 1999); whereas a number of other 
studies   show   no   relationship   (Li et al., 2010;   Schultz et al., 2007;   Tamura et al., 2000;  
Yarbrough et al., 2010). As with the human studies, a number of possible reasons may 
explain the controversial data. 
 
One of the reasons for the contrasting findings is the use of load dependent measures of 
cardiac chamber dimensions (echocardiography in vivo) in the presence of increased preloads 
(Chen et al., 2010; Gerdes et al., 2010; Kajstura et al., 1995; Tamura et al., 1998; Wang et 
al., 1999; Yarbrough et al., 2010).  As discussed above with respect to human studies, the 
increased cardiac chamber diameters and cardiac myocyte length noted in these studies may 
be indicative of the increased preloads rather than the presence of adverse chamber 
remodelling (cardiac dilatation).  
 
Secondly, in a number of studies showing an association between cardiac myocyte length and 
cardiac chamber dimension, the experimental animals (spontaneously hypertensive heart 
failure, SHHF rats) were from 12 to 16 months older than the control animals (Gerdes et al., 
1996; Tamura et al., 1998). As LV weight increases with age in hypertensive rats (Gerdes et
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Table 1.2: Summary of data from animal experimental models addressing possible association of cardiac remodelling with alterations in myocyte 
morphology 
 
Pathology/Model/Intervention Measure of 
Cardiac 
Remodeling 
Function / 
Presence of 
Heart Failure 
Method of 
Cardiac 
Assessment  
Myocyte 
Morphology 
Method of Cell 
Measurement 
Reference My Interpretation 
Dogs with pacing-induced heart 
failure (gender not stated) 
 chamber 
diameter 
 LVEDP,  
LVSP 
LV 
dimensions of 
cardiac rings 
following 
perfusion 
fixation at 
LVEDP 
measured in 
vivo  
 length Direct 
measurement of 
freshly isolated 
myocytes 
Kajstura et 
al. 1995 
As  LVEDP  in dogs with 
pacing-induced HF,  LV 
dimensions likely to be due 
to  preload 
Rats genetically predisposed to 
developing heart failure with 
increasing age (spontaneously 
hypertensive heart failure, SHHF) 
(females) 
Not done Clinical signs 
of HF 
(dyspnoea, 
cyanosis),  
liver weight,  
lung wet 
weight,  LV 
systolic 
pressure 
Catheter plus 
pressure 
transducer (in 
vivo) 
 
 length 
 
Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes 
Gerdes et al. 
1996  
 cell length in rats in HF, 
but these rats were 12 
months older than rats not 
in HF. As cardiac myocyte 
length is strongly correlated 
with age & LV weight, and 
LV weight  with age in 
hypertensive rats;  cell 
length possibly due to  
age & LV weight rather 
than  LV dimensions 
Rats genetically predisposed to 
developing heart failure with 
increasing age (spontaneously 
hypertensive heart failure, SHHF) 
(females) 
Not done No clinical 
signs of HF 
Echo (in vivo)  length 
 
Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes 
Onodera et 
al. 1998 
(Gerdes 
laboratory) 
 cell length with age 
associated with  heart 
weight/body weight with 
age in hypertensive rats 
without HF; therefore  
cell length possibly due to 
 age & heart weight rather 
than  LV dimensions 
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Pathology/Model/Intervention Measure of 
Cardiac 
Remodeling 
Function / 
Presence of 
Heart Failure 
Method of 
Cardiac 
Assessment  
Myocyte 
Morphology 
Method of Cell 
Measurement 
Reference My Interpretation 
Rats genetically predisposed to 
developing heart failure with 
increasing age (spontaneously 
hypertensive heart failure, SHHF) 
(females) 
 chamber 
circumference 
Clinical signs 
of HF (eg. 
dyspnoea, 
ascites, pleural 
effusion, 
pericardial 
effusion, 
cyanosis) 
Anatomical 
measurement 
of chamber 
circumference 
in formalin 
fixed heart 
slices 
 length 
 
Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes & 
myocytes 
isolated from 
formalin fixed 
tissue using 
potassium 
hydroxide 
Tamura et 
al. 1998 
(Gerdes 
laboratory) 
 cell length in rats in HF, 
but these rats were 16 
months older than rats not 
in HF. As cardiac myocyte 
length is strongly correlated 
with age & LV weight, and 
LV weight  with age in 
hypertensive rats;  cell 
length possibly due to  
age & LV weight rather 
than  LV dimensions 
Constriction of thoracic aorta in 
guinea pigs (males) 
 LVEDD 
 
 FS,  EF,  
LVEDP 
Echo (in vivo)  length Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes 
Wang et al 
1999 
(Gerdes 
laboratory)  
As  LVEDP  in guinea 
pigs with  FS &  EF,  
LVEDD likely to be due to 
 preload 
Rats genetically predisposed to 
developing heart failure with 
increasing age (spontaneously 
hypertensive heart failure, SHHF) 
(females) 
 LVEDD at 
22 months 
No change in 
FS 
Echo (in vivo) No change in 
length 
Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes 
Tamura et 
al. 2000 
(Gerdes 
laboratory) 
Despite  LVEDD at 22 
months, no change in cell 
length observed, hence  
LV dimensions not 
associated with  cell 
length 
 
Angiotensin II type 1 receptor 
blocker administration to SHHF 
(females) 
No change in 
LVEDD  
No change in 
FS 
Echo (in vivo)  length    cell length associated 
with  heart weight /body 
weight but no change in 
LVEDD, suggests that  
cell length in SHHF is due 
to  heart weight rather 
than  LV dimensions 
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Pathology/Model/Intervention Measure of 
Cardiac 
Remodeling 
Function / 
Presence of 
Heart Failure 
Method of 
Cardiac 
Assessment  
Myocyte 
Morphology 
Method of Cell 
Measurement 
Reference My Interpretation 
Transgenic mice with cardiac 
specific overexpression of tumour 
necrosis alpha (results in the 
development of HF) 
(males compared to females) 
 LVEDD 
only in males 
 
 FS Echo (in vivo)  length in 
males & 
females 
Direct 
measurement of 
freshly isolated 
myocytes 
Janczewski 
et al 2003 
In females,  cell length 
but no change in LVEDD, 
hence  cell length not 
associated with  LVEDD 
Cardiomyopathic hamsters (male) 
 
 
L-thyroxine administration 
Diiodothyropropionic acid (thyroid 
hormone analogue) administration 
 LVEDD 
 
 
Normalisation 
of LVEDD 
 EF 
 
 
 EF 
Echo (in vivo) No change in 
length 
 
No change in 
length 
 
Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes   
Kuzman et 
al 2007 
(Gerdes 
laboratory) 
Cell length not associated 
with LVEDD  
Spontaneously hypertensive heart 
failure (SHHF) adult rats (females) 
 
 
Long-term exercise (16 months) in 
SHHF adult rats 
 LVEDD 
 
 
 
 LVEDD, 
and > in non-
exercise SHHF 
 EF &  FS 
 
 
 
 EF &  FS, 
and < in non-
exercise SHHF; 
ascites in 42% 
of rats  
Echo (in 
vivo); catheter 
plus pressure 
transducer (in 
vivo) 
 
 length 
 
 
 
 length, 
but not 
different 
from non-
exercise 
SHHF 
Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes   
Schultz et al 
2007 
(Gerdes 
laboratory) 
 LVEDD,  EF &  FS 
associated with  cell 
length 
 
Despite greater  LVEDD, 
 EF,  FS & presence of 
ascites, no difference in cell 
length compared to non-
exercise SHHF 
Myocardial infarction (MI) via left 
coronary artery ligation in adult rats 
(males compared to females) 
 LVEDD  FS &  LV 
systolic 
pressure; 
  LVEDP 
Echo (in 
vivo); catheter 
plus pressure 
transducer (in 
vivo) 
 length 
 
Direct 
measurement of 
gluteraldehyde 
fixed freshly 
isolated 
myocytes 
Chen et al 
2010 
(Gerdes 
laboratory) 
 LVEDD,  FS,  LVSP 
&  LVEDP associated 
with  cell length; but  
LVEDD is a likely to be a 
preload induced effect 
Myocardial infarction (MI) via left 
coronary artery ligation in adult mice 
(males) 
 LVEDD 
 
 
 
 FS 
 
 
 
Echo (in vivo) No change in 
length 
 
 
Direct 
measurement of 
freshly isolated 
myocytes   
Li et al 2010 
 
 LVEDD not associated 
with   cell length 
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Pathology/Model/Intervention Measure of 
Cardiac 
Remodeling 
Function / 
Presence of 
Heart Failure 
Method of 
Cardiac 
Assessment  
Myocyte 
Morphology 
Method of Cell 
Measurement 
Reference My Interpretation 
Intramyocardial delivery of 
mesenchymal stem cells to mice 
with MI 
Prevention of 
 LVEDD 
 
Prevention of 
 FS 
Echo (in vivo)  length Direct 
measurement of 
freshly isolated 
myocytes   
Li et al 2010 
 
Normalisation of LVEDD 
associated with   cell 
length 
 preload via aortocaval shunt in 
adult mice (females) 
 
 
 LVEDD 
 
 
 
No change in 
FS 
 
 
Echo (in vivo)  length 
 
 
 
Direct 
measurement of 
freshly isolated 
myocytes   
Toischer et 
al 2010 
 cell length prior to  FS 
 
 
MI via ligation of circumflex 
coronary artery in adult pigs (gender 
not stated) 
 
 
Caspase inhibition to pigs with MI  
 LVEDD 
 
 
 
 
 LVEDD, but 
< in absence of 
caspase 
inhibition 
 LVEDP 
 
 
 
 
 LVEDP 
 
 
Echo (in 
vivo); catheter 
plus pressure 
transducer (in 
vivo) 
 
No change in 
length 
 
 
 
 length 
 
Direct 
measurement of 
myocytes from 
formalin-fixed 
tissue   
Yarbrough  
et al 2010 
 LVEDD & in HF ( 
LVEDP) but no change in 
cell length 
 
 
 LVEDD & in HF ( 
LVEDP) but  cell length 
 
, increase;  decrease; echo, echocardiography; EF, ejection fraction; FS, fractional shortening; HF, heart failure; LV, left ventricle; LVEDD, left 
ventricular end diastolic diameter; LVEDP, left ventricular end diastolic pressure; LVSP, left ventricular systolic pressure; PCWP, pulmonary capillary 
wedge pressure; PWTd, posterior wall thickness in diastole; SHHF, spontaneously hypertensive heart failure; ,  and no change are in comparison to 
control group unless otherwise stated  
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al. 1996), and cardiac myocyte length is strongly associated with age in SHHF rats (Tamura 
et al., 1998) and with LV weight (Campbell et al. 1991; Capasso et al. 1992), the increases in 
cardiac myocyte length observed in the experimental groups may reflect age induced 
changes, rather than an association with adverse chamber remodelling (cardiac dilatation) and 
the development of heart failure. 
 
Thirdly, data from various intervention studies failed to show changes in cardiac dimensions 
in parallel with changes in cardiac myocyte length. In intervention studies where increases in 
cardiac chamber diameter were prevented by thyroid hormone administration (Kuzman et al., 
2007) or intramyocardial delivery of mesenchymal stem cells (Li et al., 2010), either no 
change (Kuzman et al., 2007) or even increases in cardiac myocyte length (Li et al., 2010) 
were noted. Alternatively, in one study decreases in cardiac myocyte length were noted 
subsequent to angiotensin II receptor blockade, but no changes in cardiac chamber 
dimensions were noted (Tamura et al., 2000). Furthermore, in a study of the effects of long-
term exercise in rats with heart failure, further increases in cardiac chamber dimensions due 
to exercise training were not accompanied by further increases in cardiac myocyte length 
(Schultz et al., 2007). The results from the intervention studies discussed above, although 
different from each other, do not show parallel changes in cardiac chamber dimensions and 
cardiac myocyte length. Therefore the results of these studies do not support a role of changes 
in cardiac myocyte length in cardiac dilatation. Indeed, if increases in cardiac myocyte length 
were causally related to adverse cardiac remodelling, a reduction in cardiac myocyte length 
should be accompanied by a decrease in cardiac chamber dimensions. Hence the data 
provides no clear conclusion as to the possible role of cardiac myocyte length in adverse 
chamber remodelling. In fact, it could be concluded that there is no causal relationship. 
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However, the data need to be interpreted with caution in view of the use of load dependent 
measures of cardiac dimensions in these studies. 
 
Lastly, few studies have made direct comparisons of animals with cardiac pathology which 
have heart failure to animals with the same cardiac pathology but without heart failure. The 
only studies which have used this study design have been done in SHHF rats (Gerdes et al., 
1996; Tamura et al., 1998 and 2000). However, in these studies the rats in heart failure were 
from 12 to 22 months older than the rats not in heart failure. As discussed above, as cardiac 
myocyte length is associated with age (Tamura et al., 1998), the increased cardiac myocyte 
length may reflect increased age rather than increased cardiac dimensions. Indeed, a study by 
Onodera et al. (1998) showed that cardiac myocyte lengthening increased with age and 
occurred well before the development of heart failure in SHHF rats. Although the study by 
Onodera et al. (1998) suggests that changes in cardiac myocyte length are not responsible for 
the development of heart failure, no measurements of cardiac dimensions were made in this 
study. To my knowledge no study to date has compared age-matched animals with the same 
cardiac pathology which have heart failure to those without heart failure.   
 
Hence the data obtained from animal experimental models to date are equally confusing and 
hence the question of the relationship between cardiac myocyte length and adverse cardiac 
chamber remodelling remains unresolved.  
 
1.5       PROBLEM STATEMENT AND STUDY OBJECTIVES 
 
In summary, despite a plethora of studies aimed to address the relationship between cardiac 
dimensions and cardiac myocyte length, to date the data are controversial (Tables 1.1 and 1.2, 
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and Figure 1.4). As discussed the data are limited by the use of load dependent measures of 
cardiac dimensions; the comparison of hearts from humans of different gender and body size; 
the comparison of hearts from rat groups of different age and body size; and a failure to make 
direct comparisons between age-matched animals with cardiac pathology who are in heart 
failure and those who are not in heart failure. Hence, the role of cardiac myocyte length in 
adverse cardiac remodelling needs to defined using load independent measures of chamber 
dimensions and in age-matched animals where direct comparisons are made between animals 
with cardiac pathology who are in heart failure and those who are not in heart failure. 
 
To address the limitations discussed above, I chose to study two models of cardiac dilatation 
in pressure-overload induced cardiac hypertrophy in rats. The first model of cardiac dilatation 
was a natural progression model in that it involved the use of 23 month old SHR. In SHR 
older than 21 months of age, left ventricular hypertrophy is noted to progress to left 
ventricular decompensation, dilatation and heart failure in approximately half of the rats 
(Bing et al. 1995; Norton et al. 1997; Tsotetsi et al. 2001). The second model of cardiac 
dilatation, a pharmacological model, was induced in 14 month old SHR by chronic beta-
adrenoreceptor activation [daily administration of the beta-adrenergic agonist isoproterenol 
(ISO) for a period of 4.5 months]. Chronic beta-adrenoreceptor activation in SHR, has been 
shown enhance the progression from compensated left ventricular hypertrophy to left 
ventricular dilatation (Badenhorst et al. 2003b; Gibbs et al. 2004). In both of these models the 
rats in heart failure were age-matched to the rats not in heart failure and comparisons were 
made with an age-matched healthy control group. Importantly, in my studies I used load 
independent measures (determination of filling pressures at controlled volumes) to define 
cardiac dilatation.   
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Figure 1.4 Schematic representation of the factors known to contribute to cardiac 
dilatation; whereas the role of cardiac myocyte lengthening is still 
controversial.  
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The studies in this dissertation aimed to determine the role that cardiac myocyte lengthening 
in the development of adverse chamber remodelling (cardiac dilatation) that occurs in 
pressure-overload states in rats.  
The specific objectives of my studies were: 
 to compare the length of cardiac myocytes isolated from SHR rats in heart failure to 
those isolated from SHR rats without heart failure (natural progression model)   
 to compare the length of cardiac myocytes isolated from SHR rats receiving 
isoproterenol (rats in heart failure) to those isolated from SHR rats not receiving 
isoproterenol (rats without heart failure) (pharmacological model)   
 to compare the cardiac dimensions (measured using load independent measures), of 
SHR rats in heart failure to those isolated from SHR rats without heart failure 
(natural progression model)   
 to compare the cardiac dimensions (measured using load independent measures), of 
SHR rats receiving isoproterenol (rats in heart failure) to those isolated from SHR 
rats not receiving isoproterenol (rats without heart failure) (pharmacological model)   
 to determine the relationship between cardiac myocyte length and cardiac dimensions 
measured using load independent measures (both natural progression model and 
pharmacological model)   
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2.     METHODS 
 
In order to assess the role that changes in cardiac myocyte dimensions have on the 
development of dilatation, two models of cardiac dilatation in pressure-overload induced 
cardiac hypertrophy in rats were used. All studies in this dissertation were approved by the 
Animal Ethics Screening Committee (AESC) of the University of the Witwatersrand (AESC 
Clearance Numbers 1997:44:5; 1999:01:2b; 2002:37:5; 2002:39:5 & 2006:41:5). The rats 
were obtained from the Central Animal Services (CAS) Unit of the University of the 
Witwatersrand, Johannesburg, South Africa.  
 
2.1     RAT STRAINS AND GROUPS 
 
For both models of cardiac dilatation in pressure-overload induced cardiac hypertrophy, I 
used spontaneously hypertensive rats (SHR), which are a strain of rats bred to have increased 
blood pressures (Gerdes et al. 1996; Tamura et al. 1998; Tsotetsi et al. 2001). As a 
consequence of chronically elevated blood pressures, SHR develop left ventricular 
hypertrophy after 11 months of age (Norton et al. 1997).   The first model of cardiac 
dilatation was a natural progression model in that it involved the use of 23 month old SHR 
(n=18). In SHR older than 21 months of age, left ventricular hypertrophy is noted to progress 
to left ventricular decompensation, dilatation and heart failure in approximately half of the 
rats (Bing et al. 1995; Norton et al. 1997; Tsotetsi et al. 2001). The second model of cardiac 
dilatation, a pharmacological model, was induced in 14 month old SHR (n=9) by chronic 
beta-adrenoreceptor activation [daily administration of the beta-adrenergic agonist 
isoproterenol (ISO) for a period of 4.5 months]. Chronic beta-adrenoreceptor activation in 
SHR, has been shown to enhance the progression from compensated left ventricular 
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hypertrophy to left ventricular dilatation (Badenhorst et al. 2003b; Gibbs et al. 2004). In this 
arm of the study, an SHR group receiving twice daily administration of the vehicle of 
isoproterenol (saline) for a period of 4.5 months (SHR-Control, n=9), served as the ‘non-
failure’ group (see Figure 2.1 below). 
 
The control group for this study comprised of 23 month old Wistar Kyoto (WKY) rats (n = 9; 
Kleinterfarm Madorin Ltd, Germany). These rats are the genetic controls for SHR (Tsotetsi et 
al. 2001). The WKY control group acted as such for both the natural progression model as 
well as the pharmacological model of the study (see Figure 2.1 below), as these rats are 
normotensive, and are not known to develop heart failure. Although the WKY control group 
of rats were older (23 months old) than the SHR-Control and SHR-ISO rats (both 18.5 
months old), in normotensive rats in which body weight and heart weight are stable, age has 
been shown to have no impact on myocyte dimensions (Bai et al. 1990; Onodera et al. 1998; 
Tamura et al. 1998). We have previously reported no differences in body weight or left 
ventricular weight in 21-22 month old WKY compared to 12 month old WKY (Badenhorst et 
al. 2003b). Moreover, as it has previously been shown that chronic administration of a beta-
adrenergic agonist to the WKY strain of rats does not induce cardiac dilatation (Badenhorst et 
al. 2003b; Gibbs et al. 2004) I did not include a WKY group receiving chronic beta-
adrenergic agonist administration.  
 
The rats were housed in pairs in cages in the CAS Unit of the University of the 
Witwatersrand and given food and water ad libitum until termination at 18.5 or 23 months of 
age. 
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Figure 2.1 Flow chart detailing the groups of rats 
.  
The control group acted as such for both models. In the natural progression model, rats found 
to have pathological features of cardiac failure (see 2.2.1 below) were assigned to the failure 
group, and rats without any features of cardiac failure were assigned to the non-failure group. 
In the pharmacological model, the beta-adrenergic agonist, isoproterenol (or its vehicle, 
saline) was administered from 14 months of age until termination at 18.5 months of age. 
ISO, isoproterenol; SHR, spontaneously hypertensive rats; WKY, Wistar-Kyoto rats.  
Non -
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2.1.1  Natural Progression Model 
Eighteen 14 month old SHR (OLAC, UK) were housed in the CAS Unit of the University of 
the Witwatersrand. At 23 months of age the rats were terminated. At the time of termination, 
the rats were assessed for signs and symptoms of cardiac failure (see 2.2.1 below). Rats noted 
to have pathological features of cardiac failure were assigned to the failure group (SHR 
Failure, n=9), and rats without any features of cardiac failure were assigned to the non-failure 
group (SHR Non-Failure, n=9). 
 
2.1.2  Pharmacological Model 
Eighteen 14 month old SHR (OLAC, UK) were randomly assigned to two groups of nine rats 
each. One group (SHR-ISO) received a twice daily intraperitoneal injection of the beta-
adrenergic agonist isoproterenol (ISO) (Imuprel, Adcock Ingram), at a concentration of 0.02 
mg/kg/injection, in a volume of approximately 0.2 ml for 4.5 months. The other group (SHR-
Control) received a twice daily injection of the vehicle of ISO (0.2 ml of 0.9% saline) for 4.5 
months.  The rats were terminated at 18.5 months of age. 
 
2.2     SYSTOLIC BLOOD PRESSURE 
 
Non-invasive systolic blood pressures (SBP) were assessed in all rats prior to the end of the 
study using a tail-cuff technique. In the pharmacological model, these measurements were 
obtained at least 24-hours after the last dose of ISO. To familiarise the rats to the procedure, 
rats were placed in restrainers, the tail pre-warmed and the tail cuff inflated every 15 minutes 
for an hour a day on five separate days prior to the measurements. To determine SBP, rat tails 
were pre-warmed until the tail artery pulse could be detected with a photoelectric diode 
coupled to a Model 29 pulse amplifier (IITC Inc.). A tail-cuff coupled to a pressure 
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transducer was placed on the rat tail proximal to the photoelectric diode and inflated until the 
tail pulse disappeared. The tail cuff pressure was then slowly released until the tail artery 
pulse returned. Systolic BP was taken as the cuff BP at which the tail artery pulse returned.  
Recordings of the tail cuff pressure and the pulse were made on a Beckman dynograph model 
R511A recorder, the recordings of which were calibrated both before and after each 
recording. 
 
2.3     LEFT VENTRICULAR GEOMETRY 
 
Rats in the pharmacological model (at 18.5 months of age), rats in the natural progression 
model (at 23 months of age) and the WKY control rats (at 23 months of age) were 
anaesthetised using an intraperitoneal injection of ketamine (75 mg/kg) and xylazine (15 
mg/kg) (Bayer HealthCare, Animal Health). Once anaesthetised, a 14-gauge needle was 
placed in the trachea for positive pressure ventilation using room air through a constant–
volume respirator (Harvard Apparatus, South Natuck, Massachusetts). The air in the 
ventilator was supplemented with oxygen to ensure adequate oxygen saturation.  
 
The right carotid artery was catheterized using PP50 tubing. Placement of the carotid catheter 
allowed for the manual manipulation of ventricular filling as well as the measurement of 
systolic and diastolic arterial pressures and heart rate. A midline thoracotomy (sternotomy) 
was then performed.  
 
Prior to performing a parietal pericardectomy, in the 23 month old rats (natural progression 
model), careful assessment was made for the presence of pleuropericardial effusions (the 
effusion was either in the pleura and/or the pericardium; see 2.2.1 below). Piezo-electric 
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ultra-sonic transducers, attached to a previously validated apparatus (Woodiwiss & Norton 
1995; Trifunovic et al. 1995), were then placed across the short axis of the beating left 
ventricle (LV). These transducers emit ultra-sonic waves through one transducer (anteriorly, 
B in Figure 2.2) and receive the ultra-sonic waves through the other (posteriorly, C in Figure 
2.2). The distance between the transducers was measured using a calibrated sonomicrometer 
(Triton Technology). The transducers were used to measure the external diameter of the left 
ventricle through the phases of the cardiac cycle over a range of left ventricular filling 
pressures (upper panel Figure 2.3).  
 
The filling pressures were measured by means of the insertion of a 21-gauge needle through 
the apex of the heart (A in Figures 2.2 and 2.3). The 21-gauge needle was attached to a 
saline-filled PP25 polyethylene catheter which was coupled to a Gould P50 pressure 
transducer. The fluid filled catheter had amplitude-frequency responses which were uniform 
to 10Hz (Norton et al. 1997). Filling volumes were modified by the infusion of an iso-oncotic 
solution via the carotid catheter (Badenhorst et al. 2003b; Norton et al. 1997; Woodiwiss & 
Norton 1995; Tsotetsi et al. 2001). The frequent occurrence of extra systolic beats at filling 
pressures below 2 mm Hg prevented the collection of data at pressures below 2 mm Hg. The 
left ventricular end diastolic (LVED) diameters were therefore measured over a range of 
filling pressures between 2 mm Hg and 9 mm Hg.   
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Figure 2.2 Intraventricular pressure monitoring and piezo-electric ultrasonic 
transducers 
 
Diagrammatic representation of the apical catheter (A) and the apparatus used for the 
placement of the piezo-electric ultrasonic transducers (B and C) across the short axis of the 
left ventricle. A, apical catheter attached to 21-gauge needle; B, anterior (transmitting) 
transducer; C, posterior (receiving) transducer.  
 
A 
B 
C 
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Figure 2.3 Example of recordings of left ventricular external diameter 
measurements 
 
 
Example of recordings of LV external diameter (LVExtD) obtained from the piezo-electric 
ultrasonic transducers (B and C in figure 2.2) and of LV diastolic pressure obtained from the 
apical catheter (A in figure 2.2) inserted into the left ventricle.  
LVEDP, LV end diastolic pressure 
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All recordings were made on a Beckman Dynograph Recorder (type R511A). Left ventricular 
end diastolic radius (LVEDr) was calculated from the LVED external diameter 
measurements, using the following equation (Weber et al. 1988), 
 
LVED radius =  
 
where, 
LV wall volume = 0.943 x LV wet weight 
 
and where 0.943 represents the density of cardiac tissue (Tsotetsi et al. 2001; Woodiwiss and 
Norton 1995).  
 
Left ventricular end diastolic wall thickness (LVEDh), was then determined using the 
equation, 
 LVEDh = [(LVED external diameter-2 x LVEDr]/2 
 
 
(Tsotetsi et al. 2001; Woodiwiss & Norton 1995); and from these measurements, LVED wall 
thickness to radius ratio (h/r) was calculated.  
 
Using these values LVEDP-LVEDr and LVEDP-LVEDh/r relations were constructed in 
order to assess left ventricular geometry.  
2.3.1  Identification of Failure and Non-failure Rats 
In the natural progression model, rats were classified as in heart failure based upon the 
presence of pleuropericardial effusions and / or atrial thrombi. As stated above (see 2.2), at 
the time of thoracotomy and prior to pericardectomy careful assessment was made to identify 
3 
]  Volume [¾  wall LV   -
3 
] diameter / 2   external   [LVED π 
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the presence or absence of pleuropericardial effusions. In addition, the presence or absence of 
atrial thrombi was identified at post-mortem (see 2.3 below).  
 
Those animals that were found to have one or more of these pathological features of heart 
failure were assigned to the ‘SHR-Failure’ group (see Figure 2.1). Those rats that did not 
exhibit any pathological features of heart failure were assigned to the ‘SHR-Non-Failure’ 
group (see Figure 2.1). In order to confirm the presence of heart failure wet liver weights 
were determined in the SHR rats in the natural progression model and in the WKY control 
rats.   
 
2.4     TISSUE SAMPLING 
 
Once the collection of data to assess left ventricular geometry had been completed, a high 
dose (16mM) of potassium chloride (Hearse et al. 1975) was infused via the catheter into the 
carotid artery, hence arresting the heart in diastole. The heart was then removed, blotted dry 
and weighed. The right ventricular free wall was dissected away from the left ventricle and 
the left and right ventricles were weighed. During the dissection of the heart, the atria were 
removed and carefully inspected for the presence of thrombi (one of the features of heart 
failure).  
 
Samples from the left ventricle were stored at –70 ˚C for later analysis. The samples were 
carefully labelled so that cardiac myocytes could be isolated from the same region of each 
heart for accurate comparisons.  
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2.5     MYOCYTE ISOLATION  
 
Cardiac myocytes were isolated from the frozen tissue samples using a modification of a 
technique previously described (Diffee & Nagle 2003; Gerdes et al. 1998; Tamura et al. 
1998). A sharp blade was used to carefully section off a 20 mg (wet weight, for light 
microscopy) or 100 mg (wet weight, for flow cytometry) piece of the LV posterior wall from 
the same region of each rat heart. Each piece of LV tissue was of full thickness, in that it 
extended from epicardium to endocardium.  
 
Calcium-free physiological saline solution (PSS) was made for the cardiac myocyte isolation 
process. PSS consisted of NaCl 120 mmol, KCl 10 mmol, KH2PO4 1.2 mmol, MgCl2 2.6 
mmol, glucose 10 mmol, taurine 20 mmol, pyruvate 6.2 mmol and HEPES (4-(2-
hydroxyethyl)-piperazine-1-ethanesulfonic acid hemisodium salt) 4.8 mmol dissolved in 100 
ml of distilled water (all chemicals obtained from Sigma Chemical Co., St. Louis, MO). 
100ml of PSS was prepared for every 20mg of LV tissue. The PSS solution was titrated with 
10 mM NaOH droplets until the pH of the solution was equal to a pH of 7.40 (physiological 
pH). The pH was measured using a pH meter (Beckman Φ32 pH meter, Beckman 
Instruments, Inc. USA). For every 20 mg of LV tissue, 50 ml of incubation solution and 50 
ml of wash solution were prepared as described below. 
 
The incubation solution consisted of 15 mg Collagenase Type 2 (Worthington Biochemical 
Corporation, Lakewood NJ, USA) at a concentration of 317 U/mg, 14mg of Hyaluronidase 
(Worthington Biochemical Corporation, Lakewood NJ, USA) at a concentration of 581 
U/mg, 125 mg of bovine serum albumin (Fraction V, Sigma Chemical Co., St. Louis, MO) 
and 0.0227 ml of 110 mM CaCl2 dissolved in 50 ml of PSS.  The CaCl2 (Sigma Chemical 
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Co., St. Louis, MO) was prepared by dissolving 1.617g of CaCl2 into 100 ml of distilled 
water.  
 
The wash solution consisted of 0.045 ml of 110 mM CaCl2 and 250 mg of bovine serum 
albumin. 
 
The sample of LV tissue was minced and then placed in a tissue culture flask containing 10 
ml of the incubation solution. The tissue culture flask was then placed in a preheated (37 ˚C) 
oscillating water bath. The sample was oscillated in the water bath at a rate of 60 cycles per 
minute (slow shake), for a period of ten minutes. The incubation solution was then aspirated 
and a further 10 ml of fresh incubation solution was added to the flask with the tissue, 
followed by a second ten minute period of oscillations at the same rate. The incubation was 
then aspirated, and a 10 ml of fresh incubation solution was added. For the third period of 
oscillations the cycle rate was increased to 120 cycles per minute for a period of 15 minutes. 
Throughout the oscillation procedure the incubation solution containing the tissue was gassed 
with 95% O2 – 5% CO2. 
 
The flask was then removed from the water bath, two thirds of the incubation solution 
aspirated and the remainder of the contents of the flask (incubation solution containing 
digested tissue and tissue precipitants) were flushed through a 250-μm nylon mesh into a 15-
ml polypropylene test tube. The remaining tissue was then gently flushed through the nylon 
mesh using ~10 ml of the wash solution. The sample was then left to settle for 15 minutes 
after which the top two thirds of the supernatant was aspirated and ~10 ml of fresh wash 
solution was added to the test tube. Following a second settling step of 15 minutes the 
supernatant was aspirated without disturbing the pellet of cells. The cells were then diluted in 
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PSS containing 0.01% bromophenyl blue (The Coleman and Bell Co., USA) which stains 
proteins, hence allowing for the easy identification of striations (sarcomere bands) within the 
cardiac myocytes (Figure 2.4). The diluted cell sample was then aliquoted into tissue culture 
dishes for analysis under light microscopy. Approximately 55-75% of the cells in the 
suspension were rod-shaped cardiac myocytes (Figure 2.4). 
 
2.6     LIGHT MICROSCOPY 
 
LV tissue from all rats in both models (natural progession and pharmacological) plus LV 
tissue from the WKY control group of the study, was assessed under light microscopy. Using 
an inverted light microscope (A, Figure 2.5), images seen under the microscope were relayed 
to a computer program using a digital camera (B, Figure 2.5) (Nikon Digital Sight DS-U1 & 
DS-5M, Nikon Corporation, Japan). The cells were viewed at 400x magnification and cardiac 
myocytes were selected based on the ability to see and count most of the sarcomere bands 
from one end of the cardiac myocyte to the other (Figure 2.6). Between 25 and 30 cardiac 
myocytes were selected from each LV tissue sample. Using the program, Act2U (Ver. 1.70 
Nikon Corporation, Japan), the dimensions of each cardiac myocyte were measured. The 
software was calibrated using a 0.01 x 100 = 1mm graticule (Graticules Ltd, Tonbridge, Kent, 
England). All images were saved on hard drive before being assessed. Saving of the images 
ensured that the cardiac myocyte images were not moving during the measurements and that 
the measurements could be reassessed at anytime. The dimensions measured were the length 
(A, Figure 2.6), width (B, Figure 2.6) and sarcomere length (distance between Z-bands) (C, 
Figure 2.6) of each cardiac myocyte. The length to width ratio of each cardiac myocyte was 
calculated. The 30-35 cardiac myocyte dimensions obtained were then averaged for each 
sample of LV tissue. From these group means were then calculated.    
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4  Examples of isolated cardiac myocytes 
 
An example of ~70% rod-shaped isolated cardiac myocytes (A) surrounded by cell debris, 
non-viable cardiac myocytes or cells which are not cardiac myocytes (B) (upper panel) and a 
rod-shaped isolated cardiac myocyte (lower panel) 
A 
A 
B 
B 
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Figure 2.5  Photograph of digital camera and microscope 
 
 
Photograph showing inverted microscope (A) to which digital camera (B) is attached. The 
digital camera is coupled to a computer running Act2U software and an image of a cardiac 
myocyte is displayed on the computer screen (C).  
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Figure 2.6 An example of striations of an isolated cardiac myocyte 
 
Photograph of a cardiac myocyte showing striations and the measurement of length (A), 
width (B) and sarcomere length (C).  
A 
B 
C 
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2.7     FLOW CYTOMETRY 
 
As using light microscopy, relatively few cardiac myocytes can be measured in comparison 
to the total number of cardiac myocytes, I wished to also determine cardiac myocyte 
dimensions using a procedure which allows for the measurement of vast numbers of cells 
(~30 000 cells) in a short period of time. In order to do this I devised a method to measure 
cardiac myocyte dimensions using flow cytometry based upon previously described methods 
(Diez & Simm 1998; Nash et al. 1979). For the assessment of cardiac myocyte dimensions 
using flow cytometry, cardiac myocytes were isolated from 100mg of LV tissue from each of 
the rats (those in the natural progression model; those in the pharmacological model and the 
WKY control rats) using the same procedure as described above (see 2.4). However, after 
cardiac myocyte isolation, the cells were not stained with bromophenol blue; they were 
suspended in 1ml of PSS and placed in 5ml Polystyrene round bottom tubes (Falcon, Becton-
Dickinson, USA) rather than in cell culture dishes. 
 
Cardiac myocyte morphometry was assessed using a Becton-Dickinson flow cytometer 
(FACSCalibur
®
, Franklin Lakes, NJ) (see Figure 2.7). Fluorescence in the FL1 channel was 
quantified at a single cell level and data were analysed using Cellquest
®
 version 3.3 (Becton 
Dickinson software). The flow cytometer was preset to measure a maximum of 30 000 cells 
per sample. The cardiac myocytes were not stained as they autofluoresce, hence allowing for 
their detection and the assessment of their forward and side scatter. Side scatter gives an 
indication of cell granularity (number of intracellular organelles and/or proteins) and forward 
scatter a measure of relative cell size (based upon the shape of the cell and the degree of 
folding of the cell membrane). A dot plot of side versus forward scatter (Figure 2.8) was then 
drawn. The side versus forward scatter dot plot was then gated (A, Figure 2.8) to exclude 
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debris and cells which are not cardiac myocytes (cells with low granularity) (Strijdom H et al. 
2004). 
 
The measurement of cell length by the flow cytometer was achieved by the determination of 
the time of flight (FL1-W). The cardiac myocytes are passed through the flow chamber 
through which the excitation light source is shone at 90°. The longer the cardiac myocytes 
are, the greater is the period of time that the cardiac myocytes are in the path of the laser 
beam (called the time of flight) (Figure 2.9). Hence longer cardiac myocytes have a greater 
time of flight or FL1-W (Figure 2.10). In order for this measurement of cardiac myocyte 
length to be calibrated rod-shaped beads would be required. As at present only cylindrical 
calibration beads are available, I have indicated these cardiac myocyte length measurements 
as unitless. FL1-W measurements of ~15 000 to 20 000 cardiac myocytes were obtained for 
each LV specimen. From these measurements group means were calculated. 
 
2.8     STATISTICAL ANALYSES 
 
All data were compared between the five groups in the two models of dilatation; i.e. the 
SHR-Failure and SHR-Non-Failure for the natural progression model; the SHR-Control and 
SHR-ISO treated groups for the pharmacological model and the WKY control group. An 
analysis of variance (ANOVA) was performed followed by a Student-Newman-Keuls post-
hoc test to assess for differences between the groups. The relations between cardiac myocyte 
length and LVED radius; light microscopy cardiac myocyte length and flow cytometry 
cardiac myocyte length; and cardiac myocyte length and LV weight normalised to 100g body 
weight were determined using linear correlation analysis (Pearson’s). All data are represented 
as mean  SEM (standard error of the mean). The significance level was set at p<0.05.  
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Figure 2.7 Flow cytometer 
 
A photograph of the Becton-Dickinson flow cytometer (FACSCalibur
®
). 
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Figure 2.8 Example of flow cytometer dot plot 
 
Dot plot of side scatter height (SSC-H) and forward scatter height (FSC-H) of cardiac 
myocytes. The dot plot was gated (A) from a SSC-H of above 200 in order to exclude debris 
and cells which are not cardiac myocytes [cells with low granularity (SSC-H)]. 
 
A 
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Figure 2.9 Diagrammatic representation of a cardiac myocyte in the path of the flow 
cytometer laser beam 
 
Diagrammatic representation of a cardiac myocyte (A) in the path of the laser beam (B). As 
indicated in the graph, the time of flight counts (y-axis) increase as the cardiac myocyte 
passes from ~⅓ (1) to the whole (3) of the cell being in the path of the laser beam. 
Counts 
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Figure 2.10 Plot of cardiac myocyte counts versus time of flight 
 
Plot of counts versus time of flight (FL1-W) for cardiac myocytes from a normotensive WKY 
rat (purple), a SHR-NF rat (light pink) and a SHR-F rat (dark pink).  
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CHAPTER 3 
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3.0     RESULTS 
3.1     LEFT VENTRICULAR GEOMETRY 
3.1.1   Natural Progression Model 
3.1.1.1  Body and Tissue Weights and Blood Pressures 
Both heart weight and LV weight were increased in the SHR-Failure and SHR-Non-Failure 
groups when compared to the WKY control group (Table 3.1). However, the body weights of 
the WKY control group were greater than those of both the SHR-Failure and the SHR-Non-
Failure groups. Nevertheless, LV weight standardised to 100g body weight remained 
increased in both the SHR-Failure and the SHR-Non-Failure groups compared to the WKY 
control group (Table 3.1). Consistent with the increased heart and LV weights, both SHR 
groups had increased SBP compared to the WKY group (Table 3.1). 
 
Despite similar body weights; heart weight, LV weight and LV weight normalised to 100g 
body weight ratio were greater in the SHR-Failure group compared to the SHR-Non-Failure 
group. Consistent with the presence of heart failure, both RV weight and wet liver weight 
were increased in the SHR-Failure group compared to the SHR-Non-Failure group and the 
WKY control group (Table 3.1).  
3.1.1.2  LV Dimensions  
The LV end diastolic radius of the SHR-Failure group was significantly greater than that of 
the SHR-Non-Failure group throughout the measured LV end diastolic pressure range of 2 – 
9 mm Hg (Figure 3.1, upper panel), but was only greater than that of the WKY control group 
at an LV end diastolic pressure of 9 mm Hg. Bearing in mind the increased body weight in 
the WKY control group, the LV end diastolic radius was normalised to 100g body weight. 
Throughout the measured LV end diastolic pressure range of 2-9 mm Hg, the LV end 
diastolic radius normalised to 100g body weight was greater in the SHR-Failure group 
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Table 3.1 Body and tissue weights in the natural progression model and in the pharmacological model 
 
 Normotensive control Natural progression model Pharmacological model 
 WKY SHR-Non-Failure SHR-Failure SHR-Control SHR-ISO 
Number 9 9 9 9 9 
Body weight (g) 418±6 344±9*** 336±8*** 360±6*** 353±10*** 
Heart weight (g) 1.35±0.03 1.75±0.03*** 1.96±0.03***†‡ 1.67±0.07** 2.01±0.13***##§ 
LV weight (g) 0.99±0.02 1.32±0.02*** 1.50±0.02***†‡ 1.29±0.06*** 1.53±0.11***#§ 
LV weight / 100g body weight 0.238±0.006 0.383±0.009*** 0.446±0.011***†‡ 0.359±0.013*** 0.437±0.034***##§ 
RV weight (g) 0.36±0.01 0.41±0.01 0.48±0.01***††‡‡ 0.38±0.02 0.48±0.02***###§§ 
Liver weight (g) 13.10±0.38 13.48±0.48 15.41±0.75*† - - 
Systolic blood pressure (mmHg) 128±8 188±7*** 190±8*** 186±6*** 188±9*** 
 
Values are mean ± SEM. The WKY normotensive group was the control group for both models. 
*p<0.05, **p<0.01, ***p<0.001 compared to the WKY control group; †p<0.05, ††p<0.001 compared to the SHR-Non-Failure group; #p<0.05, 
##p<0.01, ###p<0.001 compared to the SHR-Control group; ‡p<0.05, ‡‡p<0.01 versus SHR-Control group; §p<0.05, §§p<0.01 versus SHR-
Non-Failure group. 
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Figure 3.1 Left ventricular end diastolic radius – pressure relations in the natural 
progression model 
 
Left ventricular (LV) end diastolic radius – pressure relations (upper panel) and these 
relations after normalising LV radius to 100g body weight (BW) (lower panel) for the three 
groups in the natural progression model.  
*p<0.05, **p<0.01, ***p<0.001 compared to the WKY control group; †p<0.05, ††p<0.01, 
†††p<0.001 compared to the SHR-Non-Failure group. 
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compared to those of the SHR-Non-Failure group and the WKY control group (Figure 3.1, 
lower panel). The increased LV end diastolic radius normalised to 100g body weight in the 
SHR-Failure group is indicative of the presence of LV dilatation.   
 
Throughout the measured LV end diastolic pressure range of 2-9 mm Hg, the LV end 
diastolic wall thickness to radius ratio was higher in the SHR-Non-Failure group compared to 
that of the WKY control group, consistent with compensatory concentric geometry (Figure 
3.2). Moreover the LV end diastolic wall thickness to radius ratio in the SHR-Failure group 
was decreased compared to that of the SHR-Non-Failure group and was no different to that of 
the WKY controls (Figure 3.2). The decreased LV end diastolic wall thickness to radius ratio 
in the SHR-Failure group is consistent with the presence of LV decompensation and 
dilatation.  
3.1.2  Pharmacological Model     
3.1.2.1  Body and Tissue Weights 
Body weight was lower but heart weight and LV weight were greater in the SHR-Control and 
SHR-ISO groups when compared to the WKY control group (Table 3.1). In addition, the 
SHR-ISO group had significantly greater heart weight and LV weight than the SHR-Control 
group (Table 3.1). Furthermore, the LV weight normalised to 100g body weight of the SHR-
Control and SHR-ISO groups was greater than that of the WKY control group. Moreover, the 
LV weight normalised to 100g body weight of the SHR-ISO group was greater than that of 
the SHR-Control group (Table 3.1). In the SHR-ISO group, RV weight was increased 
compared to both the SHR-Control and the WKY groups, consistent with the presence of LV 
failure in the SHR-ISO group. 
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Figure 3.2 Left ventricular end diastolic wall thickness to radius ratio – pressure 
relations in the natural progression model 
 
Left ventricular (LV) end diastolic wall thickness to radius ratio – pressure relations for the 
three groups in the natural progression model.  
*p<0.05, **p<0.01 compared to the WKY control group; †p<0.05, ††p<0.01 compared to the 
SHR-Non-Failure group. 
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3.1.2.2  LV Dimensions  
The LV end diastolic radius of the SHR-ISO group were increased compared to those of both 
the WKY control and the SHR-Control groups throughout the measured LV end diastolic 
pressure range of 2 – 9 mm Hg (Figure 3.3, upper panel), indicative of the presence of LV 
dilatation in the SHR-ISO group. Similarly, the LV end diastolic radius normalised to 100g 
body weight was increased in the SHR-ISO group compared to both the SHR-Control and the 
WKY control groups throughout the measured LV end diastolic pressure range of 2-9 mm Hg 
(Figure 3.3, lower panel). No differences were noted between the SHR-Control and WKY 
control groups.   
 
Indicative of the presence of compensatory concentric geometry, the LV end diastolic wall 
thickness to radius ratio at LV end diastolic pressures of 2-6 mm Hg was increased in the 
SHR-Control group (Figure 3.4). In comparison, at LV end diastolic pressures of 2-6 mm Hg, 
the LV end diastolic wall thickness to radius ratio in the SHR-ISO group was lower than that 
of the SHR-Control group and was no different from that of the WKY control group (Figure 
3.4). The decreased LV end diastolic wall thickness to radius ratio in the SHR-ISO group is 
indicative of LV decompensation and dilatation.  
 
3.2     MYOCYTE DIMENSIONS 
3.2.1   Natural Progression Model                                                                              
3.2.1.1  Light microscopy 
There was a significant increase in the length of the cardiac myocytes of the hypertensive 
groups (SHR-Failure and SHR-Non-Failure groups) when compared to the normotensive 
(WKY) group (Figure 3.5, upper panel). Importantly, there was no difference in the cardiac 
myocyte lengths between the two hypertensive groups. Hence, despite the presence of LV 
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Figure 3.3 Left ventricular end diastolic radius – pressure relations in the 
pharmacological model 
 
Left ventricular (LV) end diastolic radius – pressure relations (upper panel) and these 
relations after normalising LV radius to 100g body weight (BW) (lower panel) for the three 
groups in the pharmacological model.  
*p<0.05, **p<0.01, ***p<0.001 compared to the WKY control group; ##p<0.01, ###p<0.001 
compared to the SHR-Control group. 
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Figure 3.4 Left ventricular end diastolic wall thickness to radius ratio – pressure 
relations in the pharmacological model  
 
Left ventricular (LV) end diastolic wall thickness to radius ratio – pressure relations for the 
three groups in the pharmacological model.  
*p<0.05, **p<0.01 compared to the WKY control group; #p<0.05, ##p<0.01 compared to the 
SHR-Control group. 
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dilatation, the SHR-Failure rats had cardiac myocytes of similar length to those of the SHR-
Non-Failure rats (absence of LV dilatation) (Figure 3.5, upper panel). Consistent with an 
increased cardiac myocyte length in the hypertensive groups, a right shift in the frequency 
distribution of cardiac myocyte lengths was noted in the SHR-Non-Failure and SHR-Failure 
groups in comparison to the WKY control group (Figure 3.5, lower panel). 
 
No differences were noted for either cardiac myocyte width (Figure 3.6, upper panel) or the 
cardiac myocyte length to width ratio (Figure 3.6, lower panel) between the SHR-Failure, 
SHR-Non-Failure and WKY groups. In addition no differences in sarcomere length (μm) 
(WKY: 1.87±0.04; SHR-Non-Failure: 1.99±0.04; SHR-Failure: 2.00±0.04) or sarcomere 
number (WKY: 45±2; SHR-Non-Failure: 46±2; SHR-Failure: 46±2) were noted between the 
three groups. 
 
3.2.1.2  Flow Cytometry 
The data collected from the same rat hearts using flow cytometry indicated a similar pattern 
as that shown with light microscopy. The length (FL1W) of the WKY cardiac myocytes was 
significantly decreased as compared to that of the two hypertensive groups, SHR-Failure and 
SHR-Non-Failure (Figure 3.7). Moreover, no differences in cardiac myocyte length (FL1W) 
were noted between the SHR-Failure and the SHR-Non-Failure groups (Figure 3.7), 
indicating that despite differences in LV dimensions (Figures 3.1 and 3.2), no differences in 
cardiac myocyte length (FL1W) were noted.   
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Figure 3.5 Cardiac myocyte lengths and frequency distribution of cardiac myocyte 
lengths in the natural progression model 
 
Cardiac myocyte lengths (upper panel) and frequency distribution of cardiac myocyte lengths 
(lower panel) as assessed by light microscopy in the three groups of the natural progression 
model.  
***p<0.001 compared to the WKY control group. 
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Figure 3.6 Cardiac myocyte widths and length to width ratios in the natural 
progression model  
 
Cardiac myocyte widths (upper panel) and length to width ratios (lower panel) as assessed by 
light microscopy in the three groups of the natural progression model.  
No significant differences were noted between the three groups. 
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Figure 3.7 Cardiac myocyte lengths as assessed by flow cytometry in the natural 
progression model 
 
Cardiac myocyte lengths as assessed by flow cytometry (FL1W) in the three groups of the 
natural progression model.  
*p<0.05, **p<0.01 compared to the WKY control group. 
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3.2.2 Pharmacological model 
3.2.2.1  Light microscopy 
There was a significant increase in the length of the cardiac myocytes of the SHR-Control 
and SHR-ISO groups when compared to those of the normotensive WKY control group 
(Figure 3.8, upper panel). Importantly, there was no difference in the length of the cardiac 
myocytes of the SHR-ISO group compared to those of the SHR-Control groups (Figure 3.8, 
upper panel). Hence, despite the presence of cardiac dilatation in the SHR-ISO group, but not 
in the SHR-Control group, the cardiac myocyte length was no different between these two 
groups. Consistent with an increased cardiac myocyte length in the hypertensive groups, a 
right shift in the frequency distribution of cardiac myocyte lengths was noted in the SHR-
Control and SHR-ISO groups in comparison to the WKY control group (Figure 3.8, lower 
panel). 
The cardiac myocyte widths of the SHR-ISO and SHR-Control groups were no different from 
those of the WKY control group (Figure 3.9, upper panel). In addition, no differences in the 
cell length to width ratios were noted between the three groups (Figure 3.9, lower panel). A 
modest increase (p<0.05) in sarcomere length (μm) was noted in SHR-Control (2.10±0.04) 
and SHR-ISO (2.13±0.04) in comparison to WKY (1.87±0.04). However, no differences in 
sarcomere number (WKY: 45±2; SHR-Control: 40±2; SHR-ISO: 40±2) were noted between 
the three groups. 
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Figure 3.8 Cardiac myocyte lengths and frequency distribution of cardiac myocyte 
lengths in the pharmacological model 
 
Cardiac myocyte lengths (upper panel) and frequency distribution of cardiac myocyte lengths 
(lower panel) as assessed by light microscopy in the three groups of the pharmacological 
model.  
*p<0.05 compared to the WKY control group. 
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Figure 3.9 Cardiac myocyte widths and length to width ratios in the pharmacological 
model 
 
Cardiac myocyte widths (upper panel) and length to width ratios (lower panel) as assessed by 
light microscopy in the three groups of the pharmacological model.  
No significant differences were noted between the three groups. 
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3.2.2.2 Flow Cytometry 
The data collected from the same rat hearts using flow cytometry indicated a similar pattern 
as that shown with light microscopy. The length (FL1W) of the WKY cardiac myocytes was 
significantly shorter as compared to that of the SHR-Control and SHR-ISO groups (Figure 
3.10). Importantly, despite differences in LV dimensions (Figures 3.3 and 3.4) no difference 
in cardiac myocyte length (FL1W) was evident between the SHR-ISO and SHR-Control 
groups (Figure 3.10).  
 
3.3     CORRELATIONS 
3.3.1  Left ventricular end diastolic radius and cardiac myocyte length 
Linear correlation analyses between LV end diastolic radius and cardiac myocyte length 
(Figure 3.11, light microscopy, upper panel and flow cytometry, lower panel) were performed 
using data from all groups (SHR-Non-Failure, SHR-Failure, WKY, SHR-Control, SHR-ISO). 
Despite a range of light microscopy mean myocyte lengths (~70-110 μm) and mean LV end 
diastolic radii (~0.1-0.6 cm), no correlation was observed (Figure 3.11, upper panel). 
Furthermore, no correlation was observed between flow cytometry myocyte lengths and LV 
end diastolic radii (Figure 3.11, lower panel). 
3.3.2  Cardiac myocyte lengths obtained using light microscopy versus flow 
cytometry                                                          
The two techniques used to measure cardiac myocyte length were linearly correlated (Figure 
3.12). The cardiac myocytes from the WKY control rats were the smallest (in the left of 
Figure 3.12) and no differences between the four SHR groups were evident (there is 
considerable overlap of the data obtained in these four groups, Figure 3.12). Using these two 
techniques the same differences were shown between the groups (compare figures 3.5 and 
3.7; compare Figures 3.8 and 3.10). Hence, although absolute measurements of cell length 
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Figure 3.10 Cardiac myocyte lengths as assessed by flow cytometry in the 
pharmacological model 
 
Cardiac myocyte lengths as assessed by flow cytometry (FL1W) in the three groups of the 
pharmacological model.  
*p<0.05 compared to the WKY control group. 
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Figure 3.11 Linear correlation analyses between left ventricular end diastolic radius 
and cardiac myocyte length 
 
Linear correlation analyses between left ventricular (LV) end diastolic radius and cardiac 
myocyte length as assessed by light microscopy (upper panel) and flow cytometry (lower 
panel) using data obtained in all groups.  
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Figure 3.12 Linear correlation analysis between cardiac myocyte length measured 
using light microscopy and flow cytometry 
 
Linear correlation analysis between cardiac myocyte length measured using light microscopy 
(y-axis) and cardiac myocyte length assessed using flow cytometry (FL1W, x-axis) using 
data obtained in all groups.  
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cannot be obtained using flow cytometry, due to the inability to calibrate at present, 
differences in cardiac myocyte length between groups can be assessed using this technique. 
3.3.3 Left ventricular weight (mg/100g body weight) versus cardiac 
myocyte length  
A strong association was noted between LV weight normalised to 100g body weight and 
cardiac myocyte length measured using either light microscopy (Figure 3.13, upper panel) or 
flow cytometry (Figure 3.13, lower panel). 
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Figure 3.13 Linear correlation analyses between left ventricuar weight normalised to 
100g body weight and cardiac myocyte length as assessed by light microscopy and flow 
cytometry 
 
Linear correlation analyses between left ventricular (LV) weight normalised to 100g body 
weight and cardiac myocyte length as assessed by light microscopy (upper panel) and flow 
cytometry (lower panel) using data obtained in all groups.  
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4.0     DISCUSSION 
 
The main findings of the present study are as follows: The length of cardiac myocytes 
isolated from rats with LV dilatation (SHR-Failure and SHR-ISO) was no different from the 
length of cardiac myocytes isolated from rats without LV dilatation (SHR-Non-Failure and 
SHR-Control). The two models of LV dilatation used [natural progression model (SHR-
Failure) and pharmacological model (SHR-ISO)] revealed the same outcome that LV 
dilatation (increased LV end diastolic radius and decreased LV wall thickness to radius ratio) 
is not associated with an increase in cardiac myocyte length. Furthermore, the data were 
confirmed using two methods (light microscopy and flow cytometry) to determine cardiac 
myocyte length. However, the hypertensive rats (SHR-Non-Failure; SHR-Failure; SHR-
Control; SHR-ISO) did have an increased cardiac myocyte length compared to that of 
normotensive rats (WKY control). 
 
The present study clarifies that although alterations in cardiac myocyte dimensions 
accompany hypertension-induced cardiac hypertrophy (Bishop et al. 1979; McCrossan et al. 
2004; Olivetti et al. 1994; Zierhut et al. 1991), further increases in cardiac myocyte length are 
not a mechanism of the development of cardiac dilatation and heart failure. The present study 
is the first study to assess cardiac myocyte dimensions in age-matched animals with cardiac 
dilatation and to accurately determine LV dilatation using load independent measurements. 
Our data showing that LV dilatation is not associated with increases in cardiac myocyte 
length are in contrast to a number of studies mostly from the same group (Chen et al., 2010; 
Gerdes et al. 1996; Onodera et al. 1998; Schultz et al., 2007; Tamura et al. 1998, 1999 and 
2000) that report increases in cardiac myocyte length in rats in heart failure.  
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As a model of heart failure, Gerdes and his colleagues (Gerdes et al. 1996; Onodera et al. 
1998; Tamura et al. 1998, 1999 and 2000) have used rats that are genetically predisposed to 
the development of heart failure with increasing age (spontaneously hypertensive heart 
failure, SHHF). Consequently, in all of their studies the rats with heart failure were 3 to 16 
months older than those rats not in heart failure (Gerdes et al. 1996: 24 versus 12 months; 
Onodera et al. 1998: 12 versus 9 months; Tamura et al. 1998, 1999 and 2000: 18 versus 2, 16 
versus 6 and 22 versus 18 months respectively). As cardiac myocyte length is strongly 
correlated with age in SHHF rats (Tamura et al. 1998) and with LV weight (Campbell et al. 
1991; Capasso et al. 1992; current study), and LV weight increases with age in hypertensive 
rats (Gerdes et al. 1996), the increased cardiac myocyte length observed in the SHHF rats 
with heart failure may be attributed to the increased age and hence LV weight of these rats 
rather than the presence of increased LV dimensions and heart failure. Moreover, in a study 
to assess reverse remodelling, an angiotensin II type 1 receptor blocker resulted in a decrease 
in myocyte length associated with a decrease in heart weight but no change in LV internal 
dimensions in age-matched SHHF rats (Tamura et al. 2000). In addition, although differences 
in cardiac myocyte length and heart weight between the angiotensin II type 1 receptor blocker 
treatment group and the hydralazine treatment group were noted, no differences in LV 
internal dimensions between these two groups were evident (Tamura et al. 2000).    
 
Few previous studies have simultaneously measured cardiac myocyte length and LV 
dimensions. Most studies reporting increases in cardiac myocyte length in rats with heart 
failure compared to rats without heart failure have failed to measure LV dimensions (Gerdes 
et al. 1996; Onodera et al. 1998; Tamura et al. 1998 and 1999). Hence, whether increases in 
cardiac myocyte length accompany LV dilatation is not evident from these studies. Moreover, 
the few studies which have assessed LV dimensions have used in vivo echocardiography, 
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which is dependent on loading conditions and heart rate. Hence the increases in LV 
dimensions reported previously (Tamura et al. 2000) may be as a consequence of increases in 
loading conditions rather than the presence of LV remodelling and dilatation. Indeed in 
SHHF rats increases in LV internal dimensions are accompanied by increases in LV systolic 
wall stress (afterload) (Tamura et al. 2000) and decreases in LV internal dimensions occurred 
when LV systolic wall stress was reduced (Tamura et al. 2000). Similarly, in both aortic 
banded guinea pigs (Wang et al. 1999) and supraventricular tachycardia-induced 
cardiomyopathy in pigs (Spinale et al. 1996), increases in LV internal dimensions were 
measured in the presence of increases in afterload (systolic wall stress) and preload (LV end 
diastolic pressure). Furthermore, the reductions in LV end diastolic diameter reported 
following LV assist device support are likely to be due to the decreases in pulmonary 
capillary wedge pressure (preload) as a consequence of LV assist device support (Zafeiridis 
et al. 1998). Although, one previous study did not use echocardiography, they measured LV 
dimensions of cardiac rings following perfusion fixation (Kajstura et al. 1995), in which the 
perfusion pressure was maintained equal to the LV end diastolic pressure measured in vivo. 
As the LV filling pressure was increased in the dogs with pacing-induced heart failure, the 
increased LV dimensions reported are likely to be attributed to the increased preload 
(Kajstura et al. 1995). Moreover, reductions in cardiac myocyte length have been reported 
when cardiac preload and/or afterload are decreased (Campbell et al. 1991; Cooper et al. 
1982 and 1984; Thompson et al.1984). In contrast in the present study, LV dilatation was 
defined as the presence of an increased LV end diastolic radius and a decreased LV end 
diastolic wall thickness to radius ratio determined over a range of controlled LV filling 
volumes in vivo. Hence, the increases in LV dimensions in the current study are an accurate 
indication of the presence of LV dilatation independent of loading conditions.  
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A further explanation for the discrepancy between our data and that of others may be the 
difference in the strain of rats used. In the studies by Gerdes and colleagues (Gerdes et al. 
1996; Onodera et al. 1998; Tamura et al. 1998, 1999 and 2000) the SHHF model has been 
used predominantly. However, the genetic background of the SHHF rat strain differs from 
that of the SHR and WKY rat strains (McCune et al. 1990; 1995a and 1995b). Moreover, the 
SHHF rat strain is reported to have longer cardiac myocytes than normal adult rats (Gerdes et 
al. 1996), a difference that was noted long before the development of the clinical signs and 
decreased hemodynamic function associated with heart failure (Onodera et al. 1998). 
Typically SHHF rats not in heart failure have cardiac myocyte lengths of ~140 to 150 μm 
(Capasso et al. 1992; Tamura et al. 1999), whereas mean cardiac myocyte lengths of 109 to 
145 μm and 94 to 110 μm have been reported in the Sprague-Dawley (Bai et al. 1990; 
Korecky & Rakusan 1978; Nash et al. 1979) and Fischer (Bishop & Drummond 1979) strains 
of rats respectively. Similar to the results of the present study, previous studies reported 
longer cardiac myocytes in SHR compared to WKY rats (Aiello et al. 2004; Bishop et al. 
1979; Brooksby et al. 1992; McCrossan et al. 2004). In these previous studies cardiac 
myocyte lengths ranged from 93 to 140 μm in WKY and from 105 to 150 μm in SHR (Aiello 
et al. 2004; Bishop et al. 1979; Brooksby et al. 1992; McCrossan et al. 2004) and in the 
present study we report mean cardiac myocyte lengths of 76 μm in WKY rats and 86 to 96 
μm in SHR. Hence, even within rat strain there is a wide range of cardiac myocyte lengths. 
Differences within strain may be related to differences in the origin of the rats, as those SHR 
and WKY obtained from the same source have similar cardiac myocyte lengths (Bishop et al. 
1979: WKY=93 μm and SHR=105 μm; Brooksby et al. 1992: WKY=95 μm and SHR=115 
μm; both from Charles River Breeding Laboratory); whereas WKY and SHR from a different 
source (bred in the researchers own facility as opposed to from Charles River Breeding 
Laboratory) have different cardiac myocyte lengths (WKY=136 μm and SHR=147 μm; 
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Aiello et al. 2004). Similarly, Sprague-Dawley rats obtained from different sources (Bio-
Breeding Laboratories: Korecky & Rakusan 1978 versus Holtman Company: Bai et al. 1990) 
have different cardiac myocyte lengths (120 μm: Korecky & Rakusan 1978; 145 μm: Bai et 
al. 1990). In this regard the SHR used in the present study were bred in the Central Animal 
Services at the University of the Witwatersrand. The original breeding pairs were obtained 
over 20 years ago from OLAC, UK. It has also been reported that differences in cardiac 
myocyte size can be present in different shipments of a given strain of rats (Campbell et al. 
1991). In addition, cardiac myocyte lengths vary across species. Mean cardiac myocyte 
lengths of 122 to 137 μm have been reported in normal adult hamsters (Sorenson et al. 1985) 
and in normal adult guinea pigs mean cardiac myocyte length is 168 μm (Wang et al. 1999). 
   
It may also be argued that the method of cell isolation may impact upon cardiac myocyte 
dimensions. Fixation after isolation does not appear to impact upon cardiac myocyte length 
(freshly isolated: 109 μm; fixed: 109 μm; Nash et al. 1979); however, plated cardiac 
myocytes are longer (147 μm, Fraticelli et al. 1989) than those freshly isolated (110 μm, 
Sorenson et al. 1985) from the same strain of rat of the same age (Wistar). Nevertheless, 
Diffee and Nagle (2003), who used a similar method of isolation as in the present study (ie. 
from frozen tissue) report cardiac myocyte lengths of 123 μm which are no different from 
those of cardiac myocytes freshly isolated (120 μm, Korecky and Rakusan 1978) from the 
same strain (Sprague Dawley) of  rats of the same age. Hence it is unlikely that the method of 
cell isolation used in the present study had an impact on the cardiac myocyte lengths 
recorded. Furthermore, the slack (relaxed) sarcomere lengths of 1.87 μm (WKY) and 1.99 to 
2.13 μm (SHR) recorded in the present study are similar to those recorded in previous studies 
1.60 μm (Fischer: Bishop and Drummond, 1979), 1.62 μm (Wistar, WKY and SHR: Bishop 
et al. 1979), 1.80 μm (Sprague-Dawley: Korecky & Rakusan 1978) 1.81 μm (WKY) and 1.85 
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μm (SHR) (McCrossan et al. 2004), 1.83 μm (Wistar: Fraticelli et al. 1989), 1.88 μm (SHHF: 
Gerdes et al. 1996), 1.90 μm  (Sprague-Dawley: Diffee & Nagle 2003; SHHF: Tamura et al. 
1998) and 1.95 μm (WKY and SHR: Brooksby et al. 1992). 
   
Lastly, the discrepancy between the results of our study and that of previous studies may be 
related to differences in the models of LV dilatation and heart failure. Besides the SHHF rat 
model (Gerdes et al. 1996; Onodera et al. 1998; Tamura et al. 1998, 1999 and 2000), cardiac 
myocyte lengths have been assessed in two other models of heart failure, namely 
supraventricular tachycardia-induced cardiomyopathy in pigs (Spinale et al. 1996) and dogs 
(Kajstura et al. 1995), and constriction of the descending thoracic aorta in guinea pigs (Wang 
et al. 1999). Consistent with the SHHF model, in these two models increases in cardiac 
myocyte length have been reported in the group with increased LV end diastolic dimensions 
(Kajstura et al. 1995; Spinale et al. 1996; Wang et al. 1999).  However, as cardiac dilatation 
has been attributed to alterations in both cardiac myocyte dimensions and myocardial fibrosis 
in dilated cardiomyopathy in humans (Beltrami et al. 1995), and changes in myocyte volume 
are reported to correlate with alterations in heart mass unless there is extensive fibrosis 
(Gerdes, 2002), it is important to assess the relative contribution of each of these factors to 
LV remodelling. In this regard, Campbell et al. (1991) attribute increases in heart weight 
despite no change in cardiac myocyte size to increases in myocardial fibrosis. Importantly, in 
the SHHF model only modest increases in myocardial collagen content (an increase from 1.9 
to 2.5%; Onodera et al. 1998; Tamura et al. 1998) have been noted. Similarly, there is a lack 
of myocardial fibrosis in the aortic banding model (Wang et al. 1999), and in tachycardia-
induced cardiomyopathy myocardial collagen concentrations are either decreased (Spinale et 
al. 1996) or modestly increased (from 0.5 to 6%, Kajstura et al. 1995). In contrast, in both the 
natural progression (SHR-Failure) and the pharmacological (SHR-ISO) model used in the 
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present study, we have previously shown that alterations in the characteristics of myocardial 
collagen play a major role in determining LV remodelling and dilatation (Anamourlis et al. 
2006; Badenhorst et al. 2003a and 2003b; Tsotetsi et al. 2001; Veliotes et al. 2005; 
Woodiwiss et al. 2001), data which is supported by studies showing increased fibrosis in 
SHR in heart failure (Boluyt et al. 1995; Conrad et al. 1995; Engelmann et al. 1987). Hence 
it is not surprising that we found no contribution of cardiac myocyte length to LV dilatation; 
whereas in models in which fibrosis plays little role (Kajstura et al. 1995; Onodera et al. 
1998; Spinale et al. 1996; Tamura et al. 1998; Wang et al. 1999), alterations in cardiac 
myocyte length were observed. 
 
In agreement with previous studies conducted in SHR (Boluyt et al. 1995; Conrad et al. 
1995; Engelmann et al. 1987), no changes in cardiac myocyte dimensions were noted in SHR 
with LV dilatation in the present study. In this regard, Engelmann et al. (1987) report no 
change in cardiac myocyte cross-sectional area but substantial increases in myocardial 
fibrosis in SHR with decreased LV wall thickness. Similarly, Boluyt et al. (1995) and Conrad 
et al. (1995) report decreases in cardiac myocyte fractional area and increased myocardial 
fibrosis in SHR in heart failure.  
 
Furthermore, in support of the lack of association between cardiac myocyte length and LV 
dimensions observed in the present study; Schultz et al. (2007) showed that 16 months of 
exercise in SHHF rats resulted in a 21% increase in LV diastolic diameter, but no change in 
myocyte length. The deleterious effects of exercise on cardiac remodelling (enhanced LV 
dilatation) were however associated with a profound increase in cardiac fibrosis (~140%). 
Similarly, the prevention of increases in cardiac chamber diameter, by thyroid administration 
in cardiomyopathic hamsters, was associated with no change in cardiac myocyte length 
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(Kuzman et al., 2007). In a study assessing the impact of TNF-α overexpression on cardiac 
remodelling; although cardiac myocyte length was increased in both male and female rats, 
increases in LV diastolic diameter were only observed in the male rats (Janczewski et al. 
2003). Moreover, Tamura et al., (2000) reported decreases in cardiac myocyte length 
subsequent to angiotensin II receptor blockade; however no changes in cardiac dimensions 
were noted. Lastly, increases rather than decreases in cardiac myocyte length were reported 
in a recent study in which intramyocardial delivery of mesenchymal stem cells resulted in the 
prevention of cardiac dilatation following myocardial infarction in mice (Li et al., 2010).  
 
Although a limitation of the present study may be the use of cardiac myocytes isolated from 
frozen tissue, this is unlikely. As previously discussed the lengths of cardiac myocytes 
isolated from frozen tissue (123 μm, Diffee & Nagle, 2003) are no different from those of 
freshly isolated cardiac myocytes (120 μm, Korecky & Rakusan 1978). In addition, the 
method used to isolate cardiac myocytes is more likely to impact on absolute length 
measurements than on comparisons between groups. Hence, the lack of difference in cardiac 
myocyte lengths between rats with LV dilatation (SHR-Failure and SHR-ISO) and those 
without LV dilatation (SHR-Failure and SHR-Control) is not likely to be as a consequence of 
the method of cardiac myocyte isolation. In contrast, the strengths of the present study 
include the use of two methods of measurement of cardiac myocyte length; the investigation 
of two models of cardiac dilatation; and the assessment of LV dimensions using load and 
heart rate independent measures. 
 
From a clinical perspective the present study suggests that in hypertension-induced and beta-
adrenergic induced heart failure, models in which the cardiac interstitium plays a major role, 
alterations in cardiac myocyte dimensions do not contribute to LV dilatation. Hence, in these 
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models therapy should be aimed at targeting the extracellular matrix rather than growth or 
hypertrophy of cardiac myocytes. 
 
In conclusion, the present study indicates that although cardiac hypertrophy (in both 
hypertension-induced and beta-adrenergic-induced models) is associated with increases in 
cardiac myocyte length, cardiac dilatation in these models is not attributed to alterations in 
cardiac myocyte dimensions. 
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